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ZUSAMMENFASSUNG 
 
Prostatakrebs ist weltweit eine der der am häufigsten zum Tode führenden 
Krebsarten bei Männern. Die hohe Mortalitätsrate ist das Resultat von 
Patienten mit aggressiven (z. B. schnell fortschreitend) Tumoren, die ein 
hohes Risiko der Metastasenbildung besitzen. Um die Sterberate zu 
reduzieren, haben sich Wissenschaftler darauf fokussiert die molekularen 
Mechanismen zu identifizieren und charakterisieren, die mit den Prozessen 
assoziiert sind, die die Progression von Prostatakrebs ermöglichen. Einer der 
Faktoren, die mit dem Fortschreiten der Krankheit in Verbindung stehen ist 
Anterior Gradient Homolog 3 (AGR3), ein Mitglied der Familie der 
Proteindisulfidisomerasen, die in die Proteinfaltung involviert sind. Die 
Funktion von AGR3 in der Tumorprogression ist bislang jedoch unbekannt 
und wurde daher in dieser Arbeit untersucht. 
Analysen der AGR3 Expression in Prostatakrebspatienten zeigte eine hohe 
Expression in Proben mit einem Gleason Score von 8-10, was darauf 
hinweist, dass AGR3 mit der aggressiven Krankheit in Verbindung steht. 
Knockdown Experimente in Prostatakrebszelllinien unter Verwendung von 
shRNA Lentivirenkonstrukten oder die Überexpression unter Verwendung 
eines induzierbaren Überexpressionsystems zeigten, dass AGR3 einen 
positiven Einfluss auf die Zellproliferation hat. Darüber hinaus konnte gezeigt 
werden, dass AGR3 die Migration und Adhäsion von Prostatakrebszellen 
erhöht. Die Analyse von Daten aus genome-wide Genexpressionsanalysen, in 
denen Kontroll und AGR3-knockdown VCaP Prostatakrebszellen verglichen 
wurden, ergaben eine Hochregulation verschiedener Gene, die in 
extrazelluläre Matrix-Prozesse involviert sind, eingeschlossen Lumican, ein 
sekretorisches Leucin-reiches  Glycoprotein, welches die Zellmigration 
hemmt. Anschließende knochdown-Studien zeigten, dass AGR3 seinen 
positiven Einfluss auf die VCaP Zellmigration zumindest teilweise durch die 
Suppression der Lumican-Expression ausübt. Zusätzlich zu diesen Prozessen 
könnte AGR3 eine wichtige Rolle während physiologischem Stress spielen, 
welchem Krebszellen in der Tumormikroumgebung gewöhnlich ausgesetzt 
sind. Das AGR3 Protein ist im Endoplasmatischen Retikulum von 
Prostatakrebszellen lokalisiert und ist während Endoplasmatischem 
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Retikulum-Stress hochreguliert. Die AGR3 Expression korrelierte positiv mit 
der erhöhten Expression des pro-survival Chaperons GRP78 im 
Endoplasmatischen Retikulum sowie einer erhöhten Zellviabilität.    
Zusammengefasst identifizierten diese Ergebnisse AGR3 als ein Protein, 
welches die Prostatakrebsprogression durch eine Verstärkung von 
Wachstum, Viabilität und Migration von Tumorzellen positiv reguliert.      
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ABSTRACT 
 
Prostate cancer is one of the leading causes of cancer-related death in males 
worldwide. The majority of mortality is incurred by patients with aggressive 
(i.e. rapidly progressing) tumors that carry a great risk of metastasis. To 
reduce mortality, research has focused on finding and characterizing the 
molecular events associated with processes that enable prostate cancer 
progression. One of the targets associated with the progression of the disease 
is Anterior Gradient homolog 3 (AGR3), a member of the protein disulfide 
isomerase family that is involved in protein folding. However the function of 
AGR3 in the tumor progression is not known and is therefore the object of the 
present study. 
Analysis of AGR3 expression in prostate cancer patients revealed high 
levels of expression in samples with a Gleason score of 8-10, suggesting an 
association of AGR3 with aggressive disease. Knockdown experiments in 
prostate cancer cell lines using a shRNA lentiviral construct or overexpression 
using an inducible system revealed that AGR3 exerts a positive influence on 
cell proliferation. Furthermore, AGR3 was found to enhance prostate cancer 
cell migration and adhesion. Analysis of genome-wide gene expression data 
comparing control and AGR3-depleted VCaP prostate cancer cells revealed 
upregulation of several genes involved in extracellular matrix processes 
including Lumican, a secreted leucine-rich glycoprotein known to inhibit 
prostate cancer cell migration. Subsequently, knockdown studies showed that 
AGR3 exerts its positive influence on VCaP cell migration at least in part by 
suppressing Lumican expression. In addition to these processes, AGR3 may 
play an important role during the physiological stress commonly experienced 
by cancer cells in the tumor microenvironment. The AGR3 protein localizes in 
the endoplasmic reticulum of prostate cancer cells, and is upregulated during 
endoplasmic reticulum stress. AGR3 expression correlated positively with 
enhanced expression of pro-survival endoplasmic reticulum chaperone 
GRP78 as well as increased cell viability. 
Taken together, these results identify AGR3 as a protein that positively 
regulates prostate cancer progression by increasing the growth, viability, and 
migration of the tumor cells.  
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1. INTRODUCTION 
 
 
1.1 Prostate cancer 
 
Prostate cancer is one of the leading causes of cancer-related mortality 
in males worldwide [1]. The majority of this malignancy originates in the 
prostate epithelium where the two main cell types, basal and luminal 
(secretory), form superimposed cell layers separated from the surrounding 
stroma by a sheet of extracellular-matrix fibers known as the basement 
membrane. In healthy prostate tissue and precursor stages of prostate cancer 
known as PIN (prostatic intraepithelial neoplasia), cell proliferation remains 
confined to the epithelium. In prostate adenocarcinoma, abnormal cell growth 
leads to epithelium overpopulation with luminal cells that in the advanced 
stages invade through the basement membrane and migrate to distant sites in 
the body in a process known as metastasis. Patients with advanced disease 
incur the majority of mortality, and therefore, the underlying mechanisms that 
enable abnormal epithelial cell growth to become lethal are a main focus of 
prostate cancer research.  
Luminal cell survival in the prostate epithelium is sustained by steroid 
androgens (e.g. testosterone or DHT, dihydrotestosterone). Androgens 
activate a member of the steroid nuclear receptor family (ligand-inducible 
transcription factor) known as AR (androgen receptor), which drives the 
expression of genes involved in cell proliferation and survival [2-5]. Androgen-
dependent tumors are commonly treated with ADT (androgen deprivation 
therapy) by either reducing circulating androgens through chemical castration 
(e.g. with LHRH agonists, luteinizing hormone-releasing hormone), or by 
preventing androgen from binding to AR with antiandrogens (e.g. with 
flutamide). ADT reduces the number of luminal cells by 90% mainly through 
apoptosis, and leads to a period of tumor regression [6-8]. However, in the 
majority of patients, tumor growth resumes as CRPC (castration resistant 
prostate cancer), in which AR continues to play a crucial role though gain-of-
function mutations, AR gene amplification, and upregulation of its 
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transcriptional co-activators [9-11]. CRPC patients develop metastasis in 
~30% of cases and face high mortality [12]. The limited number of treatments 
for CRPC has lead to the search for additional molecular factors that enable 
prostate cancer progression.  
 
 
1.2 Molecular features of prostate cancer progression 
 
In addition to AR, which plays a role in the majority of prostate tumors, 
there are multiple events associated with progression of prostate cancer. Of 
these, the best-characterized examples include changes in expression of key 
tumor suppressors and oncogenes through chromosomal fragment deletions 
and amplifications, epigenetic alterations, and the formation of prostate-
specific gene fusions [13]. Often, these alterations directly influence the 
activity of each other as well as the AR during prostate cancer progression.   
The most common event associated with prostate cancer progression 
is loss of heterozygosity (LOH) at chromosome 10q23, which causes 
reduction of expression of the tumor suppressor protein Pten (phosphatase 
and tensin homolog) [14]. Reduced Pten activity enables cell survival largely 
through activation of the downstream Akt (v-akt murine thymoma viral 
oncogene homolog 1) pathway [15]. Recent evidence suggests that after Pten 
deactivation, the pro-survival signal emanating from Akt promotes CRPC by 
maintaining cell growth in the absence of AR mediated survival [16].  
While sufficient to cause malignancy, deletion at chromosome 10q23 is 
typically not an isolated feature in most aggressive prostate cancers. Other 
oncogenic events, such as upregulation of the transcription factor c-Myc (v-
myc myelocytomatosis viral oncogene homolog, avian), cooperate with 
reduced Pten activity to promote disease progression [17]. c-Myc is a potent 
transcription factor known to negatively regulate genes involved in cell cycle 
arrest, induce formation of PIN, and lead to invasive adenocarcinoma [18, 19]. 
Furthermore, upregulation of MYC is inversely correlated with (and possibly 
suppresses) the expression of tumor suppressor Nkx3.1 (Nirenberg Kim 3 
homeobox 1) [20].  
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Nkx3.1 downregulation is an early event in prostate cancer progression 
present in up to 85% of PIN cases [21, 22]. The Nkx3.1 gene encodes an 
androgen regulated homeobox transcription factor, crucial to all stages of 
prostate development that drives epithelial secretory function and 
differentiation [23, 24]. Reduction of Nkx3.1 is brought about through several 
mechanisms, including frequent deletions at chromosome 8p21 and 
epigenetic suppression [23]. Nkx3.1 expression can be epigenetically 
suppressed through promoter methylation by the polycomb group gene Ezh2 
(enhancer of zeste homolog 2) [25]. Ezh2 is a H3K27 (histone 3 lysine 27) 
methyltransferase frequently upregulated in aggressive prostate malignancy 
[26, 27]. Regulation of the Ezh2 expression is in turn mediated by ERG (v-Ets 
erythroblastosis virus E26 oncogene related), which forms part of one of the 
most common gene fusion events in prostate cancer [25]. ERG is member of 
the Ets (E26 transformation specific) family of transcription factors that forms 
a prostate-specific gene fusion with androgen regulated Tmprss2 
(transmembrane protease, serine 2) in up to 50% of patients [28, 29].  The 
TMPRSS2-ERG protein product promotes a transcriptional program that 
reverses cell differentiation and promotes CRPC [30].  
Even though these lesions reveal some of the most frequent 
mechanisms that promote malignancy and lead to CRPC, they are not 
exhaustive. The search for a comprehensive catalogue of the alterations 
occurring in prostate cancer was advanced through use of genome wide 
technologies such SSH (suppressive subtractive hybridization), microarray, 
and recently RNA-seq (mRNA sequencing). These technologies have 
confirmed all previously described lesions of prostate malignancy and 
revealed a new set of events that may influence tumor progression.  
One of the most recently characterized genes implicated in prostate 
cancer progression is AGR2 (anterior gradient homolog 2) [31, 32]. Initially 
identified in an SSH screen comparing differential gene expression between 
benign and malignant patient samples, AGR2 was recently shown to be part 
of a core set of genes whose expression correlates strongly with CRCP [31, 
33]. AGR2 is an AR-regulated gene that can promote cell growth, migration, 
and invasion in prostate cancer [32, 34, 35].  
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In Homo sapiens, AGR2 has two other homologues, namely AGR3 and 
AGR1 (anterior gradient homolog 3 and 1), which share 61% and 39% protein 
sequence homology respectively. AGR3 is also AR regulated and follows a 
similar pattern of expression to AGR2 during model organism development 
(e.g. Xenopus laevis) [36-40]. These shared attributes with AGR2 suggest a 
possible role for AGR3 in prostate cancer progression. 
 
 
1.3 AGR genes are conserved and play a role in development and 
regeneration in amphibians 
  
The AGR (anterior gradient) family was first described in the tetraploid 
Xenopus laevis, which has four AGR genes and their respective 
pseudoalleles (denoted as 1/2 or a/b), namely XAG1/2 (xenopus anterior 
gradient 1/2), AGR1(a/b), AGR2(a/b), and AGR3(a/b) (anterior gradient 
homolog 1, 2, and 3) [39, 41, 42]. AGR2 and AGR3 share the highest 
sequence homology at the mRNA level and reside in the same syntenic 
fragment in the genomes of most vertebrates indicating descent from a 
tandem gene duplication event [39, 43, 44]. Protein sequence homology 
reveals that XAG(1/2), AGR2(a/b) and AGR3(a/b) are closely related (>35%) 
suggesting the possibility of functional overlap [39].  
 
 
 
  
tandem gene duplication 
 ERP18 np77 GOB-4 BCMP11 
 TLP19 AG1 AG2 AG3 
 
AGR1 XAG(1/2) ARG2 AGR3 
fish ✓ ✓ ✓ ✕ 
amphibian ✓ ✓ ✓ ✓ 
reptiles ✓ ✕ ✓ ✓ 
birds ✓ ✕ ✓ ✓ 
mammals ✓ ✕ ✓ ✓ 
 
 
 
Table 1. AGR family conservation in vertebrates and their common synonyms.  
Gene synonyms were obtained from Xanbase (http://www.xenbase.org/). Species 
conservation analysis was adapted from [39].  “✓” and “✕” denote presence or absence in the 
indicated vertebrate class. The shaded genes are closely related based on protein sequence 
homology. 
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One of the most remarkable functions of AGR genes was identified in 
the adult A. maculatum where an orthologue of XAG2, namely nAG (newt 
anterior gradient), mediates limb regeneration. nAG is expressed and 
secreted by gland cells of the wound healing epidermis after limb amputation 
where it promotes stem cell (i.e. blastema) proliferation and, through 
interaction with Prod 1, helps establish the correct identity of regenerating 
tissues [45-47]. AGR genes are thought to function similarly in X. laevis, which 
can regenerate tissues at specific stages (43-57) of development. During 
these stages, the XAG2, AGR2(a), and AGR3(a) transcripts are upregulated 
in larval stumps following limb amputation, indicating AGR gene involvement 
in amphibian appendage regeneration [39]. 
In addition to regeneration, the first AGR transcripts identified, XAG1 
and XAG2 are expressed in X. laevis development [41]. XAG mRNA is initially 
found in the anterior ectoderm and is progressively restricted to the anterior-
most segment where, when overexpressed, XAG2 (but not XAG1) is sufficient 
to induce formation of CG (cement gland, a mucus secreting ectoderm-
derived organ) [38, 41]. Strong XAG(1/2), AGR2(a), and AGR3(a) expression 
is eventually detected in the developing CG as well as other ectoderm-derived 
organs such as Otic vesicles [41].  
In higher vertebrates, the homolog of the XAG gene is deactivated 
through multiple in-frame stop codons (e.g. located through synteny on 
chromosome 2q37 in H. sapiens) (Table 1), suggesting that AGR function is 
likely to be mediated by AGR2 and AGR3, and possibly the distantly related 
AGR1 [39].  
 
 
1.4 Expression and function of AGR homologs in mice 
 
As in X. laevis, AGR (e.g. AGR2) gene expression is upregulated 
during mouse embryo development [48]. However, whereas AGR expression 
in X. laevis is found predominantly in ectoderm derived organs, AGR2 
expression in adult mice is found in the endoderm-derived epithelia of lungs 
and GI (gastrointestinal) tract [49-52]. AGR2 expression occurs mainly in 
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mucin secreting epithelial cells where it is thought to induce cell differentiation 
(e.g. promote differentiation of mucous-secreting goblet cells in intestine or 
lung epithelia) [50, 52, 53]. Furthermore, suppression of AGR2 leads to 
perturbed mucin production caused in part by disruption of AGR2–dependent 
Muc1 (pancreatic cells) and Muc2 (murine intestine epithelium) (mucin 1 or 2) 
protein processing in the ER (endoplasmic reticulum) [51, 54]. Together, 
these findings suggest a two-fold function for AGR molecules in the 
maintenance of secretory cell homeostasis and secretory protein processing 
in the ER.  
A similar function has been described in mammary gland development, 
where AGR2 suppression leads to disrupted lobuloalveolar morphology and 
reduction in milk protein expression [55]. Given its previously described role in 
ER protein folding, AGR2 expression is thought to be required during periods 
of increased protein production in differentiated secretory cells [55, 56].  
Analogous to AGR2, the mRNA of AGR3 in pregnant mice increase 
steadily until its highest point at lactation [55]. However, AGR3 transcript 
levels are consistently lower than those of AGR2, suggesting a more 
prominent role for the latter in mammary gland development and milk protein 
production.    
 Taken together, these reports implicate AGR family genes in 
mammalian development, and suggest a role in differentiated secretory 
epithelial cell homeostasis and protein processing in the ER.  
 
 
1.5 Structural features of AGR proteins 
 
The AGR genes belong to the greater PDI (protein disulfide isomerase) 
family, members of which act as chaperones and isomerases of disulfide 
bonds during protein folding in the ER. Structurally, all three genes encode 
small proteins (~17kDa) with three main features: an N-terminus cleavable 
ER-leader sequence which targets the nascent peptide for co-translational 
translocation into the ER, a thioredoxin fold which houses the catalytic 
CxxC/S motif, and a C-terminus variant of the KDEL tag that mediates 
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retention in the ER.  Localization in the ER has been demonstrated for all 
three proteins and is thought to depend on the extent of homology between 
their respective ER-retention signals with the classic KDEL motif [56-59]. The 
crystal structures of AGR1 (2K8V), AGR2 (2LNS), and AGR3 (3PH9) have 
confirmed the presence of the predicted thioredoxin-like fold for each protein 
[35, 60]. Within this fold, the AGR1 protein sequence bears the classic CxxC  
motif instead of the CxxS present in AGR2 and AGR3, suggesting reduced 
isomerase function of the latter proteins when compared to AGR1 [61].  
 
 
 
Figure 1. Protein sequence alignment of H. sapiens (h) AGR1, AGR2, and AGR3. 
Protein sequences were aligned with Clustalw2 algorithm. 
(Green) – N-terminal signaling peptide. The right-most highlighted amino acid represents the 
putative cleavage site predicted by submitting the matching accessions (hAGR1, NP_056997, 
hAGR2, NP_006399, hAGR3, NP_789783) to (http://www.cbs.dtu.dk/services/SignalP/). 
(Blue) – Putative catalytic motif CxxC/S. 
(Orange) – peptide binding loop. 
(Purple) –  C-terminal variant of the ER-retention tag.	  
 
 In addition, a region of AGR2 between amino acids 104-111, termed 
the peptide-binding loop, is able to interact with tumor suppressor protein 
Reptin [62]. A similar region is present in both AGR3 and AGR1 (Figure 1, 
orange region), but respective peptides from the homologous (but not 
identical) region failed to bind Reptin [62]. Nevertheless, the conservation of 
this region is thought to constitute a potential client-docking site for all AGR 
family members. 
AGR2 has recently been shown to dimerize through an interaction 
stabilized by an intermolecular salt bridge between E60 and K64 [35, 62]. In 
	  	   	  	  
	   	  
	  
	  
 
Introduction 
 21 
AGR3, the equivalent position of AGR2-K64 is occupied by a tyrosine residue, 
which reduces the likelihood of a stable AGR3 homodimer, but does not 
exclude the possibility of an AGR2-AGR3/1 heterodimer. Given the high 
degree of similarity between AGR2 and AGR3, it possible that they share 
other binding partners, and by extension, overlap in function and regulation.  
 
 
1.6 Transcriptional regulation of AGR genes in H. sapiens 
 
 Upregulation of AGR2 has been detected frequently in cancers. As a 
result, various studies have found diverse mechanisms of AGR2 transcript 
regulation.  
Several transcription factors involved in development, such as SMAD4 
(SMA and MAD related protein 4), ERK1/2 (extracellular regulated kinase 
1/2), and the AHR (aryl hydrocarbon receptor) regulate AGR2 expression in 
H. sapiens [54, 63, 64]. Importantly, AHR-mediated AGR2 expression was 
demonstrated under etoposide-induced (DNA-damage) implying AGR2 
promoter regulation during cellular stress [63].  
 
gene biological process transcription factor supporting literature 
AGR2 steroid hormone 
response 
ERα Vanderlaag et al., 2010; Hrstka et al., 2010 
 AR Zhang et al., 2005; Bu et al., 2011; Bu et al., 2013 
    
 cellular differentiation 
FOXA1 Zheng et al., 2006; Zhang et al., 2010 
 FOXA2 - 
  AHR Ambolet-Camoit et al., 2010 
  SMAD4 Norris et al., 2012 
  ERK1/2 Zweitzig et al., 2007 
    
 cellular stress HIF1A Hong et al., 2013 
  ATF6 Higa et al., 2011 
    AGR3 steroid hormone 
response 
ERα Al Saleh et al., 2011 
 AR Bu et al., 2013  
Table 2. Transcription factors regulating AGR2 and AGR3 expression in H. sapiens.  
A survey of AGR2 and AGR3 literature with focus on experimentally determined (i.e. reporter 
gene assays and quantitative PCR) transcription factors that regulate AGR gene expression. 
Although there is considerable overlap between the processes listed, an effort has been 
made to group transcription factors based on their most common, prominent, or better-studied 
function.  
 
Other types of cellular stress, such as those induced by lack of 
nutrients, hypoxia, or accumulation of misfolded proteins in the ER (i.e. ER 
stress) have all been shown to regulate the AGR2 promoter [31, 56, 64]. 
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During ER stress, AGR2 expression depends on transcription factor ATF6 
(activating transcription factor 6) and the activity of ER-membrane kinase 
IRE1 (inositol-requiring 1), which acts through sXBP1 (spliced x-box binding 
protein 1), an IRE1-dependent transcription factor [56]. Cellular stress induced 
by hypoxia can also regulate the AGR2 promoter in a HIF1A-dependent 
(hypoxia-inducible factor 1A) manner in glioblastoma cells, suggesting a 
possible role in the preservation of cell viability [65]. Together, these reports 
indicate frequent upregulation of AGR2 in cellular stress conditions commonly 
associated with the tumor microenvironment and its possible involvement in 
the processes that relieve them.  
AGR2 expression in cancer occurs even in the absence of simulation 
by developmental pathways or stress. In breast and prostate cancer cells, 
AGR2 expression is mediated by steroid nuclear receptors such as ER and 
AR, respectively, though the latter requires de novo protein synthesis to 
achieve AGR2 expression, given that treatment with cycloheximide (a de novo 
protein synthesis inhibitor) can block its upregulation during androgen 
stimulation [31, 32, 37, 66]. Binding of ERα (estrogen receptor α) and AR to 
cognate sites is mediated by the transcription factor FOXA1 (forkhead box A1) 
[67, 68]. Two separate reports have shown FOXA1 and FOXA2 (forkhead box 
A2, a close homolog), activity on the promoter of AGR2, though the 
significance of this interaction in nuclear-receptor mediated transcription of 
AGR2 has not been investigated [40, 69].  
As with AGR2, the AGR3 promoter is regulated by a variety of nuclear 
receptors activated by their respective ligands [37, 70]. In prostate cancer cell 
lines such as LNCaP, DUCaP, and 22Rv.1, the expression of AGR3 can be 
induced by androgen, estrogen (E2), and progesterone in an AR-dependent 
manner [37]. In contrast to AGR2 however, AR-mediated AGR3 upregulation 
is not hindered by pre-treatment of cells with cyclohexamide, indicating direct 
transcriptional regulation by AR [37]. The same study used Chip-PCR 
(chromatin immunoprecipitation coupled to polymerase chain reaction) in 
DUCaP cells to confirm AR occupancy at a previously identified binding site in 
the first intron of the AGR3 gene. In addition, AR binding sites can be readily 
identified within 25kb of the AGR3 transcription start site of LNCaP cells 
(Figure 2). Despite subtle differences, these reports suggest similar hormone-
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dependent regulation of both AGR2 and AGR3 promoters. However, these 
two genes are not always expressed together, indicating the existence of 
mutually exclusive regulation.  
 
 
 
Figure 2. AR binding sites on the distal promoter of the AGR3 gene of LNCaP cells.  
Public chip-seq datasets [30] were processed on the main Galaxy server 
(https://main.g2.bx.psu.edu) and visualized using the University of California, Santa-Cruz 
(UCSC) genome browser website (http://genome-euro.ucsc.edu). AR binding sites are 
indicated by blue arrows with 25kb of the AGR3 transcription start site. DNAseI hypersensitive 
regions are mapped on the bottom-most track.   
 
1.7 Functions of AGR2 and AGR3 in cancer 
 
In cancer, AGR2 is the most frequently upregulated member of the 
AGR family. Studies of patient survival and AGR2 expression have found 
either enhanced or poor outcome in patients with high AGR2 expression in 
their biopsy, suggesting that the relationship of this protein with cancer is 
complex [71-77]. As a result, there have been many studies investigating its 
role in various cancers, with most findings converging on three main AGR2 
functions: cell growth and transformation, metastasis, and resistance to 
endocrine and chemotherapy.  
Functional studies using various in vitro growth and migration assays, 
as well as in vivo xenografts in mice have helped clarify the properties of 
AGR2 in cancer. The ability of AGR2 to transform cells was first described in 
NIH3T3 (mouse embryonic fibroblasts) cells, in which AGR2 expression was 
sufficient to both promote enhanced growth of NIH3T3 xenografts in nude 
mice and dramatically enhance anchorage independent cell growth in soft 
agar assays [78]. Subsequently, in vitro studies using human cancer cell lines 
found that AGR2 expression is sufficient to increase cell growth, colony 
formation, and anchorage independent growth [66, 79-81]. However, a 
Scale
chr7:
LNCaP AR EtOH
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UCSC Genes (RefSeq, GenBank, CCDS, Rfam, tRNAs & Comparative Genomics)
LNCaP AR EtOH
LNCaP AR R1881
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
AGR3
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previous study using Rama 37 (non-metastatic rat mammary cells) 
overexpressing AGR2 in vivo did not find a pronounced effect on xenograft 
tumor growth, but instead reported enhanced metastasis to the lungs [82]. 
Similar AGR2 behavior was reported in prostate cancer cells where AGR2 
overexpression leads to a decrease in cell proliferation and colony formation 
in vitro, reduced tumor growth in vivo, but enhanced cell migration and 
invasion in vitro [32, 69]. 
Given that different cancers progress through distinct mechanisms it is 
possible that the reported AGR2 phenotype differences could be caused by 
the variety of cell types used to investigate its function (i.e. primary tumor or 
metastasis derived) and their tissue of origin (i.e. breast, ovarian, or prostate 
cancer). It is possible that different tumor cells exhibit only a portion of the 
wide range of AGR2 properties, which could in part explain the observed 
discrepancy between AGR2 expression and patient survival.    
AGR2 can affect patient survival by playing a role in tumor resistance 
to endocrine therapy. Tamoxifen is an antagonist of the ERα used in 
treatment of breast cancer, which results in initial tumor regression, usually 
followed by relapse with a tamoxifen-resistant phenotype sustained by 
tamoxifen-induced and ERα mediated gene expression. AGR2 is one of the 
few known genes upregulated after both estradiol and tamoxifen treatment, in 
an ERα dependent manner [80]. MCF7 cells treated with tamoxifen display 
increased survival in the presence of AGR2, suggesting a role for this protein 
in tamoxifen resistance of breast tumors [80]. Another aspect of AGR2 tumor 
biology is its ability to promote tumor cell survival after various cellular insults. 
Early on, AGR2 was shown to suppress the activation of tumor suppressor 
p53 (tumor protein 53kDa) after UV (ultra violet) radiation in H1299 cells 
(human non-small cell lung carcinoma) [79]. Another study showed that 
suppression of AGR2 in pancreatic cells (Mpanc-96) sensitized them to 
treatment with gemcitabine, a nucleoside chemotherapeutic reagent [83]. 
These findings, together with the extensive evidence linking AGR2 expression 
to cancer cell survival, suggest a role for AGR2 in resistance to therapy.  
Currently, the only functional study of AGR3 points to role in 
chemotherapeutic resistance analogous to that of AGR2. AGR3 
overexpression in ovarian cancer cells results in enhanced resistance to 
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cisplatin treatment in vivo [57]. However, in serous borderline ovarian tumor 
(an ovarian cancer primary tumor subtype), AGR3 expression correlates with 
increased cell differentiation and better prognosis, suggesting cell type 
specific functions during tumor progression [84]. In ovarian cancer, the 
expression of AGR2 and AGR3 overlaps in mucinous primary tumors, but 
follows no discernable overlapping pattern in serous, clear cell, and 
endometrial subtypes. Query of public databases (https://www.nextbio.com), 
showed that in most tissues AGR3 expression is found in epithelia of digestive 
and respiratory system in a pattern similar to that of AGR2. Furthermore, like 
AGR2, AGR3 is expressed in breast cancer patients and cell lines (i.e. T47D) 
where it correlates strongly with ERα status [43]. A similar correlation between 
ER and AGR3 expression has not been detected in ovarian cancer, a finding 
which could possibly be explained by a recently reported gene fusion event 
between the 3’ end of CUX1 (cut-like homeobox 1, chromosome 7q22) and 
the proximal promoter region of AGR3 (chromosome 7p21) in uterine 
leiomyoma [57]. This fusion event may adversely affect AGR3 regulation in 
uterine cancers and uncouple AGR2 and AGR3 expression. Over the course 
of the present study, AGR3 expression was detected throughout prostate 
cancer progression [85]. However, the function of AGR3 in prostate cancer 
remains unknown.  
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2. AIM 
 
 AGR2 and AGR3 are conserved homologs of AGR and XAG genes in 
X. laevis, which play a crucial role in development and regeneration. These 
genes lie adjacent to each other on chromosome 7p21, share a high degree 
of sequence homology, and are similarly regulated by hormone activated 
steroid receptors. The proteins of both AGR2 and AGR3 enter the 
endoplasmic reticulum where they can either be retained, or follow the 
secretory pathway to secretion. The role of AGR2 in cancer, especially that of 
the prostate, has been well characterized. To date, little is known about the 
tumor biology of AGR3.   
 
 This project aims to identify the role of AGR3 in prostate cancer. To 
accomplish this, first the influence of AGR3 in cell growth will be investigated 
in several prostate cancer cell lines. The ability of AGR3 to influence the 
spread of prostate tumor cells will be investigated using relevant assays. 
Furthermore, to provide a comprehensive view on AGR3 function, the 
influence of AGR3 in prostate cancer cell survival under stress will also be 
evaluated.  
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3. MATERIALS AND METHODS   
 
3.1 Materials 
 
3.1.a Chemicals and consumables 
 
reagent supplier 
Agarose  Peqlab, Erlangen  
Ampicillin  Roth, Karlsruhe  
Bovine Serum Albumine (BSA)  PAA Laboratories GmbH, Pasching  
Bacto-Agar  Otto Nordwald GmbH, Hamburg  
Bacto-petri dishes  Greiner Labortechnik, Nürtingen  
Bacto-Trypton  Roth, Karlsruhe  
Bacto-yeast extract  Roth, Karlsruhe  
n-buthanol  Roth, Karlsruhe  
Celltiter-Blue Promega, Mannheim 
Chloroform  Merck, Darmstadt  
Collagen I Sigma-Aldrich, Taufkirchen  
Crystal violet  Lighting Powder Company, INC.,  
Desoxy-nucleoside-triphosphate  
(dNTPs) 
Roche, Mannheim 
DiI cell labeling solution Life Technologies, Karlsruhe 
Dimethylsuloxide (DMSO)  Fluka, Neu Ulm  
Dithiothreitol (DTT)  Gibco, Invitrogen, Karlsruhe  
DNA Marker 1 Kb  PeqLab, Erlangen  
ECL (western blotting detection) Amersham Pharmacia Biotech, 
Freiburg  
Ethylenediamine Tetraacetic  
Acid (EDTA)  
Roth, Karlsruhe  
Ethanol (EtOH)  Roth, Karlsruhe  
Ethidium Bromide  Roth, Karlsruhe  
Fibronectin  Sigma-Aldrich, Taufkirchen  
FBS (Fetal Bovine Serum)  Gibco, Invitrogen, Karlsruhe  
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G418 (Geneticin)  Sigma-Aldrich, Taufkirchen  
Glycylglycerine  Roth, Karlsruhe  
Glycine  Roth, Karlsruhe  
Glycogen Peqlab, Erlangen 
Hydrogen Chloride (HCl)  Roth, Karlsruhe  
Hexadimethrine Bromide Sigma-Aldrich, Taufkirchen  
Insta-Gel Plus  
(Scintillation Counting) PerkinElmer, Waltham, USA 
Isopropanol  Roth, Karlsruhe  
Magnesium Chloride (MgCl2) Roth, Karlsruhe  
Magnesium Sulfate (MgSO4) Roth, Karlsruhe  
Methanol (MeOH)  Roth, Karlsruhe  
ß-mercaptoethanol  Roth, Karlsruhe  
Milk powder  Saliter, Obergünzburg  
Phenol  Roth, Karlsruhe  
peqGold RNA Pure Peqlab, Erlangen 
Plasmid Maxiprep Kit Qiagen, Düsseldorf 
Phosphate Buffered Saline  Gibco, Invitrogen, Karlsruhe  
Potassium Chloride  Merck, Darmstadt  
Poly-L-lysine  Sigma-Aldrich, Taufkirchen  
Rotiphorese® Gel30 (37.5:1) Roth, Karlsruhe  
RPMI medium 1640  Gibco, Invitrogen, Karlsruhe  
Protein Marker  PeqLab Erlangen  
Puromycin Calbiochem, Bad Soben 
Sodium Acetate  Roth, Karlsruhe  
Sodium Chloride  Roth, Karlsruhe  
Sodium Dodecyl Sulphate (SDS)  Roth, Karlsruhe  
Sodium Hydroxide  Roth, Karlsruhe  
Sodium N-lauryl  
sarcosinate (Sarkosyl)  
Sigma-Aldrich, Taufkirchen  
StrataClean resin Stratagene, Amsterdam 
SYBR-Green Mix Qiagen, hilden 
Tetramethyl ethylene  Roth, Karlsruhe  
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diamine (TEMED)  
Thapsigargin Life Technologies, Karlsruhe 
5'-[3H]-thymidine Hartman Analytic, Braunschweig 
Tris-base  Roth, Karlsruhe  
Tris-HCl  Roth, Karlsruhe  
Triton-X-100  Sigma-Aldrich, Taufkirchen  
Trypsin 0,025% with EDTA  Gibco, Invitrogen, Karlsruhe  
Tunicamycin Sigma, Steinheim 
Tween 20  Roth, Karlsruhe  
 
 
3.1.b Cell lines 
 
3.1.b.1 Bacteria 
 
The bacteria used to express plasmid DNA in high quantity were DH5α 
with the following phenotype:  
fhuA2 lac(del)U169 phoA glnV44 Φ80' lacZ(del)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
 
3.1.b.2 Eukaryotic cell lines 
 
prostate cell lines 
PNT2: Human prostate epithelial cell line immortalized by transfection with the 
SV40 genome, and express the large T antigen. These cells express 
cytokeratines 8, 18 and 19 which are consistent with a luminal cell phenotype. 
Cytokeratin 14, a marker of the basal phenotype is not present.  
 
BPH-1: Human epithelial cells derived from a 68 year old male with benign 
prostate hyperplasia immortalized with SV40 large T antigen. They express 
cytokeratines 8 and 18 (luminal epithelial cell phenotype). 
 
 
Materials and Methods 
 30 
 
prostate cancer cell lines 
22Rv.1: Human cell line derived from a prostate carcinoma xenograft 
(CWR22) that was serially propagated in nude mice after castration-induced 
regression and relapse of the parental, androgen dependent CWR22 
xenograft.  
 
DUCaP: Prostate cancer cell line established from the dura matter metastatic 
lesion of the autopsy of a patient with hormone refractory prostate cancer. 
These cells express the androgen receptor and cytokeratin 18 suggesting a 
luminal phenotype. This cell line produces tumors in nude mice.  
 
VCaP: Prostate cancer cell line established from the vertebral metastatic 
lesion of a patient with hormone refractory prostate cancer. These cells 
expression cytokeratines 18 and the androgen receptor suggesting a luminal 
cell phenotype. These cells express the TMPRSS2-ERG gene fusion, form 
tumors, and generate predominantly osteoblastic bone metastasis.  
 
LNCaP: Androgen dependent human cancer cell line derived fro ma needle 
aspiration biopsy of the left supraclavicular lymph node of a 50 year old 
Caucasian male with confirmed prostate metastatic cancer.  
 
LNCaP_abl: These cells are a subclone of the LNCaP cell line that was 
generated by continuously passaging in RPMI 1640 in 10% charcoal-stripped 
fetal calf serum (CCS), with the aim of obtaining an androgen independent 
cell line.  
 
PC-3: Prostate cancer cell line established from bone metastasis, with 
functional and morphologic characteristics of poorly differentiated 
adenocarcinoma. PC-3 cells lack the androgen receptor, and do not respond 
to androgen treatment. In mice, these cells are highly tumorigenic and result 
in mainly osteolytic bone metastasis.  
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DU145: Human prostate cancer cell line derived from dura matter metastatic 
lesion. These cells do not express the androgen receptor. In mice these cells 
are less tumorigenic and have lower metastatic potential than PC-3 cells 
 
other cell lines 
T47D: Human breast cancer cell line derived from the ductal carcinoma of a 
54 year old female patient. These cells were used as a positive control in 
western blotting experiments owing to their abundant expression of AGR3.   
 
 
3.1.c Oligonucleotides  
 
3.1.c.1 Oligonucleotides for PCR 
 
ß-actin:  
 forward: 5’ CTC CTG AGC GCA AGT ACT CC 3’ 
 reverse: 5’ GTC ACC TTC ACC GTT GTT CCA GT 3’ 
 
AGR3:  
 forward: 5’ GCA ATA AAA AAG GAA AAG AGG CC 3’ 
 reverse: 5’ GGG CAA ATA CTT TCT TTA GTG CTT GA 3’ 
 
3.1.c.2 Oligonucleotides for qPCR 
 
AGR3:  
 forward: 5’ CCA GAA TAC ATT TCC AAC AAG AGC A 3’ 
 reverse: 5’ GAC GAG TAA GAG GCA GAG ACC 3’ 
 
RPLP0 (RibPO): 
 forward: 5’ GAA GGC TGT GGT GCT GAT GG 3’ 
 reverse: 5’ CCG GAT ATGAGG CAG CAG 3’ 
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DMD: 
 forward: 5’ TGA TAC GGG ACG AAC AGG GA 3’ 
 reverse: 5’ ATG TTA CTG CCC CCA AAG GAT G 3’ 
 
LUM: 
 forward: 5’ CCA CAC CAC AAG ATC CCC AC 3’ 
 reverse: 5’ CCA CCA ATC AAT GCC AGG AAG A 3’ 
 
KAL1: 
 forward: 5’ TTC ACT GCC CCC AGC AAA CA 3’ 
 reverse: 5’ CAT CCG TAG TCT TTC TCC GCT TC 3’ 
 
COL5A2: 
 forward: 5’ GGTGTA CGA GGC AGT GTA GGA 3’ 
 reverse: 5’ CTG GGT GCT TTT TCG AGC CA 3’ 
 
APLP1: 
 forward: 5’ GCG TCA TGGC CCT TAT CAA CG 3’ 
 reverse: 5’ GTG TCT GCA TCC TTG GAA TCT GGA 3’ 
 
GRP78: 
 forward: 5’ GGT GCT GAT GTC CCT CTG TC 3’ 
 reverse: 5’ TTG GAG GTG AGC TGG TTC TT 3’ 
 
3.1.c.3 anti-Lumican siRNA 
 
The siRNA oligonucleotide used to knockdown Lumican expression 
was purchased from Sigma-Aldrich (Taufkirchen, Germany). The catalogue 
number is SASI_Hs01_00221304 (Mission siRNA). (sequence available upon 
request). 
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3.1.d Enzymes 
 
BamHI-HF, and XhoI restriction enzymes were purchased from New 
England Biolabs (Frankfurt, Germany). All other enzymes, (e.g. DNase, 
RNase, polymerases, and reverse transcriptases) were purchased from 
Promega (Mannheim, Germany). Specific information for each enzyme is 
provided in the following sections, which describe their use.  
 
3.1.e Plasmids 
 
pcDNA3.1 and pcDNA3.1-AGR3: 
Stable AGR3 expression was induced by transfection a pcDNA3.1 
vector (G418 and ampicillin resistance cassettes) that includes the AGR3 
cDNA. Transfection of the original pcDNA3.1 vector was carried out to 
generate control cells.  
 
shAGR3 lentiviral packaged pLKO.1-puro vectors: 
 To generate cells with a stable knockdown of AGR3, vectors containing 
shRNA sequences in pLKO.1-puro vectors (puromycin resistance cassette) 
targeting AGR3 were purchased from the MISSION shRNA line of products 
(Sigma-Aldrich). Three different sequences against AGR3 were used to 
generate separate subclones (sequences available upon request):  
Sasi_Hs01_00094948 – shRNA #1 
Sasi_Hs01_00094949 – shRNA #2 
Sasi_Hs01_00094950 – shRNA #3 
SHC002V – non-target shRNA control particles  
 
pNEB-X1-AG3:  
22Rv.1 cells with a stable transfection of the Rheo activator/receptor 
plasmid (pNEB-R1, New England Biolabs) were transfected with pNEB-X1-
hygro plasmid (hygromycin resistance cassette, New England Biolabs) 
expressing AGR3 cDNA under the control of the Rheo activator/receptor.  
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3.1.f Buffers  
 
 
1x Laemmli electrophoresis buffer 
Tris   25 mM 
Glycine  192 mM 
SDS   0.1 % w/v 
 
10x transfer buffer – western blotting 
Tris-base   58.1 g 
Glycin   29.3 g 
Methanol   20%  
diluted 1:10 in dH2O to make 1x TBS 
 
Laemmli 2x sample buffer 
SDS   4% 
ß-mercaptoethanol  10% 
Glycerol  20% 
bromophenol blue    0.004% 
Tris-HCl  125 mM 
 
TBS 10x (concentrated TBS) 
Tris-HCl   24.23 g 
NaCl   80.06 g 
dH2O   final volume 1 L 
pH   7.6 
diluted 1:10 in dH2O to make 1x TBS 
 
1x LB-medium (1 liter in dH2O) 
Trypton  10  g 
NaCl   10  g 
Yeast extract  5.0 g 
 
50x TAE buffer 
Tris-Base   40 mM 
EDTA   1 mM 
Glacial Acetic Acid   20 mM 
pH   8.9 
diluted 1:50 in dH2O to make 1x TAE 
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3.1.g Antibodies 
 
For western blotting each antibody was diluted in the indicated 
amounts and buffer and incubated with membranes for 1 h at room 
temperature or up to 24 h at 4°C. After each primary antibody incubation, the 
membrane were washed 3 times in 1xTBST and incubated for 1 h at room 
temperature with secondary antibody. Subsequently, the membranes were 
washed 3 additional times with 1x TBS-T before further processing.  
 
primary antibodies 
antibody type in 10 ml in 1x - TBS catalog # supplier 
AGR3 mouse 
monoclonal 
5.0 µg 5% w/v Milk, 5% 
v/v FBS, 0.1% v/v 
Tween20 
ab82400 Abcam 
ß-actin mouse 
monoclonal 
2.0 µg  5% w/v Milk, 5% 
v/v FBS, 0.1% v/v 
Tween20 
sc-8432 Santa 
Cruz 
α-Tubulin mouse 
monoclonal 
2.0 µg  5% w/v Milk, 5% 
v/v FBS, 0.1% v/v 
Tween20 
sc-8035 Santa 
Cruz 
GRP78 goat 
polyclonal 
3.3 µg 5% w/v Milk, 5% 
v/v FBS, 0.1% v/v 
Tween20 
sc-1050 Santa 
Cruz 
PDI mouse 
monoclonal 
5.0 µg 5% w/v Milk, 
0.1% v/v 
Tween20 
ER 
staining kit 
Invitrogen 
Lumican mouse 
polyclonal 
4.0 µg 5% w/v BSA, 
0.1% v/v 
Tween20 
ab70191 Abcam 
 
 
 
secondary antibodies 
antibody type in 10 ml solvent catalog # supplier 
anti-mouse polyclonal, 
rabbit, HRP 
conjugated 
1.0 µg 1 x TBS, 5% w/v 
Milk, 5% v/v 
FBS, 0.1% v/v 
Tween20 
P016102-
2 
Dako 
Diagnostika 
GmbH 
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anti-goat polyclonal, 
rabbit, HRP 
conjugated 
1.0 µg 1 x TBS, 5% w/v 
Milk, 5% v/v 
FBS, 0.1% v/v 
Tween20 
P044901-
2 
Dako 
Diagnostika 
GmbH 
Alexa 
Fluor 488 
anti-mouse 
rabit 
polyclonal 
2.5 µg 1x PBS, 10% v/v 
FBS 
A11059 Life 
Technologies 
Alexa 
Fluor546  
anti-Goat  
rabit 
polyclonal 
2.5 µg 1x PBS, 10% v/v 
FBS 
A11078 Life 
Technologies 
 
 
3.1.h Equipment 
 
Equipment supplier 
Sterile cell cuture CO2 incubator Labotect, Göttingen 
Centrifuge (5417R) Eppendorf, Hamburg 
Liquid Scintillation Counter Wallac ADL, Freiburg 
Tomec Cell Harvester  Wallac ADL, Freiburg 
Thermocycler (PTC 200) MJ Research, Watertown 
SetpOne Plus thermocycler (qPCR) Applied Biosystems, Darmstadt 
Waving platform shaker (Polymax 1040) Heidolph Instruments, Schwabach 
Biological safety cabinet (EN12469) ThermoScientific 
 
3.2 Methods 
 
3.2.a Cloning methods 
 
3.2.a.1 Phenol:Chloroform extraction of RNA 
 
RNA samples were extracted from eukaryotic cells by using the 
peqGOLD RNA Extraction kit (Qiagen, Hilden, Germany), which is based on 
the phenol: chloroform RNA extraction method.  For all experiments, between 
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1 and 3 x 105 cells were lysed with 1 ml peqGOLD solution over 5 min at room 
temperature. Cell lysates were supplemented with 200 µl of chloroform and 
vortex-mixed to ensure a homogeneous solution prior to 5 min of incubation at 
4°C and subsequent centrifugation for 10 min at 12.000 rpm at 4°C to 
separate protein, DNA, and RNA containing phases. The soluble RNA 
trapped in the aqueous (upper) phase was supplemented with 1:50 (v/v) 
glycogen (carrier molecule, to enhance RNA precipitation) and precipitated 
with a 1:1 (v/v) isopropanol over 15 min incubation at 4°C. Precipitated RNA 
was then pelleted by centrifuging for 10 min at 12’000 rpm at 4°C. The pellet 
was washed of residual isopropanol with 1 ml of 75% ethanol. After air-drying, 
the pellet was dissolved in 20-50 µl RNase-free water, and incubated 10 min 
at 37°C and an additional 5 min at 60°C, before measuring concentration, and 
storing at -80°C.  
 
3.2.a.2 Nucleic acid quantification 
 
Nucleic acid samples were quantified by using a Nanodrop ND-1000 
spectrophotometer (Thermo Scientific, Dreich, Germany) by measuring 
absorbance at 260, 280 and 230 nm. Samples were considered pure when 
the absorbance ratio of 260/280 nm produced values greater than 1.85 for 
DNA or 2.0 for RNA. 
 
3.2.a.3 cDNA synthesis 
 
Before cDNA synthesis, contaminant genomic DNA was digested using 
1 unit of DNase I, and 1 µl of (20-40 units/µl) RNAse inhibitor for 30 min at 
37°C for every 1 µg of RNA. The DNase digestion reaction was stopped with 
2 µl of (0.5 M) EDTA and supplemented with 200 ng of random primer, which 
was allowed to anneal for 5 min at 70°C. Subsequently, 20 µl dNTP (10 mM), 
200 units of M-MLV Reverse Transcriptase, and 4µl of 5x buffer were added 
and allowed to react in a thermocycler with an initial step of 10 min at 25°C, 
followed by 60 min at 42°C, and a final extension step of 10 min at 70°C. In 
 
Materials and Methods 
 38 
parallel, identical control reactions were carried out with 1 µg of RNA in the 
absence of M-MLV Reverse Transcriptase. After completion, each cDNA 
reaction was made to a final volume 250 µl using nuclease-free dH2O. 4 µl of 
each resulting cDNA sample and matching control (reaction without M-MLV 
reverse transcriptase) was used as template in control PCR reactions 
supplemented with 0.5 µl of (10 mM) dNTP, 10 pmol of each forward and 
reverse ß-actin primers, 1.25 units of GoTaq polymerase, 4 µL of 5x Green 
GoTaq reaction buffer, and made to a final volume of 20 µl using dH2O. In a 
thermocycler, reactions were subjected to an initial denaturation step of 2 min 
at 95°C before 30 cycles of: 30 sec denaturing at 95°C, 40 sec annealing at 
55°C, and 45 sec extension at 72°C. After a final extension step of 10 min at 
72°C, PCR products from each reaction were visualized on a 2% agarose gel 
(ß-actin band at 298 bp). All reagents were purchased from Promega, 
Mannheim, Germany. 
 
 
3.2.a.4 Polymerase chain reaction (PCR) 
 
PCR reaction (used to detect AGR3 mRNA in prostate cancer cell 
lines) was carried out using 4 µl of cDNA sample from each cell line, 
supplemented with 0.5 µl of (10 mM) dNTP, 10 pmol of each forward and 
reverse AGR3 specific primers, 1.25 units of GoTaq polymerase, 4 µL of 5x 
Green GoTaq reaction buffer, and made to a final volume of 20 µl using dH2O. 
In a thermocycler, reactions were subjected to an initial denaturation step of 2 
min at 95°C before 30 cycles of: 30 sec denaturing at 95°C, 40 sec annealing 
at 55°C, and 45 sec extension at 72°C. After a final extension step of 10 min 
at 72°C, PCR products from each reaction were visualized on a 2% agarose 
gel (AGR3 band at 99 bp). All reagents were purchased from Promega, 
Mannheim, Germany. 
 
3.2.a.5 Quantitative polymerase chain reaction (qPCR) 
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Quantitative PCR reactions were carried out by supplementing 4 µl of 
template cDNA with 10 pmol of each forward and reverse primers, 10 µl of 1X 
SYBR green mix (Promega, Mannheim, Germany), made to a final volume of 
20 µl with dH2O. In parallel, a control reaction was carried out in the absence 
of cDNA template (volume compensated with dH2O). This reaction was run in 
StepOnePlus (Life Technologies, Carlsbad, California) using this program: a 
holding stage of 95°C for 15 min, a two-step cycling stage of 95°C for 15 sec, 
then 60°C for 30 sec, followed by a melting curve with a starting temperature 
of 60°C increased in 0.5°C increments until a 95°C final step of 15 sec. 
Relative mRNA expression was calculated using the ΔΔCt method: 2^(ΔCt 
gene – ΔCt RPLP0). 
 
3.2.a.6 Nucleic acid separation by gel electrophoresis 
 
2% agarose gels were prepared to resolve the PCR products of both ß-
actin and AGR3 PCR amplification reactions. Agarose was dissolved in 1x 
TAE buffer (0.04 M Tris pH 7.2, 0.02 sodium acetate, and 1 mM EDTA). 
Before casting, the melted agarose solution was added ethidium bromide to a 
final concentration of 0.4 mg / ml and allowed to set at room temperature in 
horizontal gel chambers. The same 1x TAE buffer was used to submerge the 
agarose gel, before loading PCR reaction samples into wells. To estimate 
PCR product size, a peqGOLD DNA-leiter (0.5 mg DNA / ml) was loaded in 
parallel to samples. Electrophoresis was carried out at 120 V.  
 
3.2.a.7 Extraction of DNA fragment from agarose gel 
 
The peqGOLD gel extraction kit (peqLab Biotechnology GmbH, 
Erlangen, Germany) was used to extract DNA fragments from agarose. After 
agarose gel electrophoresis at 120 V separated DNA fragments were 
visualized under UV light and required bands excised. The gel slice was 
dissolved at 55°C in binding buffer (XP2) and the DNA captured by adding to 
a HiBind DNA spin column and centrifuging at 10000 rpm for 1 min (centrifuge 
5415D, Eppendorf). The column was washed once with 300 µl of XP2 buffer, 
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and twice more with 600 µl of SPW buffer (80% ethanol). After 3 min 
incubation, the column was dried by centrifugation for 1 min at 10000 rpm 
prior to the final elution step carried out by adding 30 – 50 µl of dH2O to the 
column and centrifuging for 1 min at 5000 rpm.  
 
3.2.a.8 DNA fragment digestion  
 
To clone the AGR3 cDNA from a pcDNA3.1-AGR3 plasmid into the 
pNEBR-X1 plasmid of the inducible expression system, 1 µg of each plasmid 
was separately digested with 10 units of each BamHI and XHoI (New England 
Biolabs, Ipswich, Massachusetts), in reactions with final concentrations of 1x 
Buffer #2 and 1x BSA for 1 h at 37°C. The reaction contents were 
supplemented with 10 µl of 5x GoTaq green reaction buffer before loading into 
2% agarose gel. After adequate separation, the AGR3 or open pNEBR-X1 
fragments were isolated from the agarose gel as described in 2.2.a.4, and the 
resulting DNA dilutions were used in a ligation reaction. An insert: plasmid 
ratio of 1:5 was used in each ligation reaction carried out by adding 1 unit of 
T4 DNA ligase in T4 DNA ligase buffer (50 mM Tric-HCl pH 7.5, 10 mM 
MgCl2, 10 mM DTT, 1 mM ATP, and 25 µg/ml BSA) in a final volume of 20 µl 
for 4 h at 16°C. The reaction was stopped by incubating its contents at 65°C 
for 10 min.  
 
3.2.a.9 Bacteria transformation with DNA plasmids 
   
50 µl of competent DH5α bacteria were incubated with 5 µl of ligation 
reaction content from 2.2.a5 for 30 min on ice before heating to 42°C for 45 
sec, placing 2 min on ice, and suspending in 1 ml of sterile SOC (0.5% yeast 
extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM of Glucose) medium. The resulting bacteria suspension 
was mixed for 30 min at 37°C and pelleted by spinning for 5 min at 3200 rpm 
before removing 900 µL of the supernatant. The bacteria pellet was 
resuspended in the remaining 100 µl of medium and streaked on a selective 
plate (1:1000 v/v LB-ampicillin) before incubation over night at 37°C.  
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3.2.a.10 Plasmid DNA purification (small scale, mini preps) 
 
Small-scale purification of plasmid DNA was carried out with a modified 
protocol of the Qiagen Plasmid Maxi Kit  (Qiagen, Hilden, Germany). 1 ml of 
cultured bacteria was pelleted at 12000 rpm for 30 sec at 4°C and re-
suspended and incubated for 5 min at RT in 100 µl of buffer P1 (10 mM 
EDTA, 50 mM Tris-HCl pH 8.0, and 400 mg/ml RNase A). The bacteria 
suspension was added 200 µl of buffer P2 (200 mM NaOH and 1% SDS), 
mixed gently, and allowed to lyse over 5 min at 4°C. 200 µl of buffer P3 (3 M 
Na Acetate, pH 8.8) was used to neutralize the lysate for an additional 5 min 
at 4°C. Precipitated debris were separated from the lysate by centrifugation at 
12000 rpm for 15 min at 4°C and transferred to new container. Thereafter, the 
DNA in the lysate was precipitated 70% isopropanol, pelleted for 10 min at 
12000 rpm, washed of isopropanol in 500 µl of 80% EtOH twice, and re-
dissolved in 20-50 µL of dH2O.  
 
 
3.2.a.11 Plasmid DNA purification (large-scale, maxi preps) 
 
Large-scale plasmid DNA purification was carried out using the Qiagen 
Plasmid Maxi Kit according to the manufacturers instructions. Cultured 
bacteria were pelleted by centrifuging at 6000 rpm for 30 min at 4°C and 
resuspended in 10 ml of buffer P1 (including RNase) for 10 min. Alkaline lysis 
was carried out for 10 min at 4°C by adding and mixing 10 ml of lysis buffer 
P2. The reaction was stopped (pH neutralized) by adding 10 ml of buffer P3. 
Subsequently, separation of cellular debris and lysate was carried out by 
centrifuging the resulting mixture at 4000 rpm at 4°C for 30 min. The 
supernatant was applied to a Qiagen Tip 500 (a anion-exchange resin 
column) previously equilibrated with 15 ml of QBT buffer (700 mM NaCl, 50 
mM MOPS pH 7.0, 15% isopropanol (v/v), 0.15%, and 0.15% (v/v) Triton X-
100). After the volume of the lysate flowed through, the column was washed 
twice with 30 ml of QC buffer (1 M NaCl, 50 mM MOPS pH 7.0, and 15% (v/v) 
isopropanol). DNA was eluted by applying 15 ml of buffer QF (125 mM NaCl, 
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50mM Tris-HCl pH 8.5, and 15% (v/v) isopropanol) and precipitated by adding 
11 ml of isopropanol prior to a 10 min incubation on at 4°C. The plasmid DNA 
was pelleted by centrifuging for at 4000 rpm for 30 min at 4°C, washed twice 
with 80% ethanol, air dried, and dissolved in dH2O.  
 
3.2.b Cell culture and transfection methods 
 
3.2.b.1   Bacterial cell culture 
 
Freshly transformed bacteria or were streaked on selection plates (LB, 
0.15% (w/v) agar, and 0.1% (v/v) agar), and colonies were allowed to form 
over night at 37°C. Bacteria colonies, or previously cultured bacteria were 
picked and applied to a suitable volume of LB medium with 0.1% (v/v) 
ampicillin, and allowed to grow overnight at 37°C while shaking at 180 rpm. 
The resulting culture was then collected and pelleted before lysis and 
purification.  
 
 
3.2.b.2   Mammalian cell culture 
   
All mammalian (adherent) cells were cultured in a humidified incubator 
at (95% humidity), at 37°C, and 5% CO2 (Forma Scientific Labortech GmbH, 
Göttingen, Germany). Cellstar culture vessels of different formats were used 
throughout this study as needed (Greiner Bio-One, Frickenhausen, Germany). 
Cells were considered confluent when visually estimated to have covered 
75% of the culture vessel growth area. At this point, cells were passaged by 
removing the culture medium, washing once with 1 x PBS, applying an 
appropriate amount of 1 x Trypsin solution with 0.25% (v/v) EDTA (Gibco – 
Life Technologies, Carlsbad, California) for 2-5 min at 37°C, deactivating the 
trypsin with 10 ml of 10% (v/v) RPMI 1640 medium, and plating a fraction of 
the resulting cell suspension new cell culture dishes as required. All cell lines 
used were cultured in 10% FBS (v/v) RPMI 1640 medium. For long-term 
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storage, 2-5 million mammalian cells were suspended in 10% DMSO (v/v) 
FBS, and allowed to thaw at -80°C for 1 day  
 
3.2.b.3   Transfection of plasmid DNA (FuGene) 
 
Cells in log-growth phase were transfected with FuGene and plasmid 
DNA according to the manufacturers instructions. Typically, each well of a 6-
well plate format was transfected with a solution of 2% plasmid DNA (w/v) of 
serum free RPMI 1640 medium (100 µl) supplemented with 6% (v/v) of 
FuGene HD reagent pre-incubated for 15 min to allow complexing of DNA to 
the components of FuGene HD. Depending on the application, 24 – 72 h were 
allowed to elapse prior to cell use.  
 
3.2.b.4   Transfection of siRNA (HiPerfect) 
   
Prior to each experiment cells were seeded in numbers that allowed for 
log-growth phase on the day of transfection. SiRNA transfection was typically 
carried out in 6-well plates. For each well, 1-2 x 105 cells growing in 1.9 ml of 
normal growth medium (RPMI 1640 and 10% (v/v) FBS) were transfected with 
a 100 µl mixture of serum free RPMI 1640 medium, containing 6 µl of 
HiPerfect transfection reagent (Qiagen, Hilden, Germany), and 5 µl of a 20 
µM stock solution of siRNA. The mixture was applied to each well drop wise. 
The final concentration of siRNA in each well was 50 nM in a final growth 
medium volume of 2 ml. For those transfections carried out in 6 cm and 10 cm 
plates the relevant cell numbers and transfection mixtures are given below.  
Format 6-well 6 cm 10 cm 
volume of stock (20 µM 
siRNA) in µl 
5 7.5 17.5 
serum free medium (µl) 100 150 350 
HiPerfect reagent volume (µl) 6.0 9.0 21.0 
 
# of cells seeded 1.0-2.0 x 105 4.0 x 105 1.5-2.0 x 106 
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3.2.b.5   Transduction of shRNA (lentiviral mediated) 
 
Transduction of VCaP cells with lentiviral particles packaging vectors 
with anti-AGR3 shRNA sequences was carried out to generate cells with a 
stable gene knockdown. According to the manufactures instructions, a 5 day 
protocol was followed. 0.5-1.0 x 104 cells were seeded in 96-well plate wells 
and allowed grow under normal growth conditions for 1 day. To enhance 
lentiviral transduction, the cell medium was replaced with 110 µl of normal 
growth medium containing 8 µg/ml of hexadimethrine bromide in addition to a 
volume of lentiviral particles containing either of three different anti-AGR3 or a 
control shRNA sequence. The multiplicity of infection (MOI) was maintained at 
2 (i.e. 2 particles per cell). After 24 h of transduction, the medium was 
replaced with 100 µl of normal growth medium and cells allowed to recover for 
an additional day. Thereafter, normal growth medium with 1 µg/ml or 
puromycin was applied to cells for selection before expansion of stable 
transfectants to larger cell culture dish formats.  
 
 
3.2.b.6   [3H]-thymidine incorporation, short-term proliferation assay 
 
1 x 103 cells were seeded in quadruplicate on two 96 well plates. One 
plate was incubated in normal incubation conditions (90% humidity, 5%CO2, 
37°C) for 1h. 20 µL of Celltiter-Blue reagent (Promega) per well was 
subsequently applied for each well to indirectly quantify the number of cells in 
each well. After another hour of incubation the plate was read at 580 nm with 
a FluoroStar Optima (BMG Labtechnologies) spectrophotometer (excitation: 
540nm, gain: 1200). These values were used to normalize the results 
obtained by the thymidine incorporation proliferation assay. Each well of the 
second 96-well plate was supplemented with 1µCi (~37kBq) of 5’-[3H]-
thymidine (Hartman Analytic, MT-846). Cells were allowed to incorporate the 
thymidine under normal cell culture conditions. After 12 h, the thymidine-
containing medium was removed, and 40µL of trypsin was added to each 
well. After a further 30 min of incubation under normal cell culture conditions, 
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the cells were harvested with a Tomtec cell harvester (Wallac-ADL) onto a 
filter mat (Perkin Elmer), which was subsequently soaked in Insta-Gel Plus 
liquid scintillation counting cocktail (Perkin Elmer) and read on a liquid 
scintillation counter (1450 Microbeta, Wallac Jet). 
 
3.2.b.7   Celltiter-Blue, long-term proliferation assay 
 
1 x 103 cells were seeded in triplicate in 96-well plates and incubated 
under normal growth conditions. 1, 24, 72, and 120 h after seeding, cells were 
supplemented with 20 µl of Celltiter-Blue reagent which was allowed to 
metabolize for 1 h prior to reading the converted dye signal at 580 nm with a 
FluoroStar Optima (BMG Labtechnologies) spectrophotometer (excitation: 
540nm, gain: 1200). Values from 24, 72, and 120 h were normalized to those 
obtained at 1 h after seeding at the beginning of the experiment. 
 
3.2.b.8   Celltiter-Blue, viability assay 
 
1 x 103 cells were seeded in quadruplicate in 96 well cell culture plates, 
and treated with either EtOH or 0.5 µM thapsigargin for 12 and 36 h. At each 
of these time points, 20 µl of Celltiter-Blue reagent was added to the cells and 
allowed to metabolize over 1 h in normal growth conditions before measuring 
fluorescence at 580 nm with a FluoroStar Optima (BMG Labtechnologies) 
spectrophotometer (excitation: 540nm, gain: 1200). % viability was calculated 
by dividing the fluorescence values of Tg treated cells to matching values of 
EtOH treated cells at each time point.  
 
3.2.b.9 Determination of protein localization by Immunofluorescence 
confocal microscopy 
 
For immunofluorescence, cells were cultured in Lab-Tek II Chamber 
Slide 8-well units (VWR International, Bruchsal, Germany) pre-coated for 24 h 
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at 37°C with a 100 µl of 1µg/ml fibronectin in 1 x PBS (Sigma-Aldrich, 
Taufkirchen, Germany). Each well was washed once with 300 µl of 1 x PBS 
prior to seeding 5 x 104 cells and incubating under normal growth conditions. 
After 24 h, the growth medium was then removed, and the cells washed once 
with 1 x PBS, prior to fixing at room temperature with 300 µl of 4% (v/v) PFA 
(paraformaldehyde). After 5 min, cells were washed 3 times with 1 x PBS and 
permibilized with 300 µl of 1 x PBS – 0.2 % (v/v) Triton X-100 solution for 5 
min at room temperature. Cells were then washed twice with 1 x PBS and 
blocked for 10 min at room temperature with a 1 x PBS with 10% (v/v) FBS 
solution. The same blocking solution was supplemented with a 0.2% (w/v) 
concentration of primary antibody and used for staining with both GRP78 
(Santa Cruz, California, USA), and AGR3 antibodies (Abcam, Cambridge, 
UK). Draq5 was diluted in 1 x PBS with 10% (v/v) FBS solution (blocking 
solution) at a final concentration of 10 µM and was used to stain the DNA in 
nuclei. Primary antibody and nuclear staining was carried out over 1 h at room 
temperature. Cells were then washed 3 x with 1 x PBS, and incubated with 
secondary antibodies. Alexa Fluor 488 Rabbit anti-Mouse (targeting AGR3) 
and 546 Rabbit anti-Goat (targeting GRP78) antibodies were diluted in the 
same blocking solution to final concentrations of 0.25 µg/ml and used in a 
volume of 200 µl. After incubating for 1 h at room temperature shielded from 
light, cells were washed 3 x with 1 x PBS, dried, and covered with PVA 
(polyvinyl alcohol) solution before being covered with a glass coverslip (Erie 
Scientific, Portsmouth, US). Immunofluorescence was visualized using a 
Zeiss LSM510 confocal microscope operated through the LSM LSe115 image 
examiner software.  
 
3.2.b.10 Endoplasmic Reticulum stress induction 
 
 Endoplasmic reticulum stress was induced in 3 x 105 cells in log-growth 
phase by applying either 0.5 µM of Tg (thapsigargin, Life Technologies, 
Karlsruhe) Tg, 0.5 µM of Tm (tunicamycin, Sigma-Aldrich), 1 mM DTT 
(dithiothreitol, Roth, Karlsruhe), or 1 µM H2O2 in a final volume of 2 ml of 
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normal growth medium (10 % (v/v) FBS in RPMI 1640). Control cells were 
treated with an equal volume of EtOH, DMSO (Fluka, Neu-Ulm), or dH2O as 
control for Tg, Tm, and DTT / H2O2 respectively. In every experiment, 
stressed cells in suspension were collected and included in all further 
analysis.  
  
3.2.b.11 Cell adhesion assay 
 
Prior to the adhesion assay, 96-well plates were coated with 100 µl of 
fibronectin (5 µg/ml) or Collagen I (10 µg/ml) serum free RPMI 1640 solution 
for 1 h at 37°C. Wells were then washed 2 times with 1x PBS to remove 
unbound substrate and blocked with 100 µl of a 10 mg/ml heat-denatured 
(65°C, 1 h) BSA solution for 30 min at 37°C. The blocking solution was then 
removed and the wells washed two times with 1 x PBS prior to assaying for 
substrate specific adhesion. Substrate specific adhesion was assayed by 
seeding 3 x 104 cells suspended in serum-free medium in quadruplicate in 
fibronectin or Collagen I (coated, and BSA-blocked (10 mg/ml, heat 
denatured) cell culture media under normal growth conditions (37°C, 5% CO2, 
and 95% humidity). Unhindered cell adhesion was estimated by seeding the 
same number of cells, suspended in normal growth medium (10% FBS (v/v) 
RPMI 1640) in uncoated wells. 1 h after seeding, cells were washed 3 times 
with 1 x PBS and fixed with 100% methanol for 5 min at room temperature. 
After fixation, the methanol was removed, and the cells were air-dried in a 
fume hood prior to staining with 0.1% w/v crystal violet solution for 30 min at 
room temperature with gentle shaking. Subsequently, cells were washed with 
water and the plate allowed to dry at room temperature. The dye trapped in 
cells was extracted with 100 µl of 10% v/v acetic acid and quantified by 
measuring absorbance at 595 nm. Substrate specificity (i.e. specific adhesion 
to either fibronectin or collagen I is reported by the signal from substrate-
coated wells as a percentage from uncoated (i.e. unhindered adherence) 
wells.  
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3.2.b.12 Chemotactic migration (modified Boyden chamber) assay   
 
Cell migration was assayed using an HTS FluoroBlok multiwell insert 
system (Becton, Dickinson Biosciences). Prior to seeding in inserts, every 1 x 
105 cells were labeled by incubating at 37°C with 1 ml of serum free RPMI 
1640 containing 1 µM Vybrant DiI live-cell labeling dye (Invitrogen, Eugene, 
Oregon). After 20 min, cells were washed once with serum free RPMI 1640 
and resuspended to a concentration of 2 x 105 / ml. To estimate the actual 
number of cells in suspension, 100 µl from each labeled-cell sample was 
seeded in a 96-well plate and the number of cells estimated by measuring 
their signal using a spectrophotometer (FLUOstar OPTIMA, BMG, excitation 
520 nm, emission 580 nm, gain 2000, scan matrix 3 x 3). These (input) values 
were used to normalize migration values and therefore minimize the impact of 
cell counting error on subsequent migration values. To avoid bubbles below 
the FluoroBlok membrane, the lower chambers of each well were added 750 
µl of chemo attractant (10% FBS in RPMI 1640) first. Subsequently, the upper 
chambers were filled with 500 µl (~1.0 x 105 stained cells) of labeled cell 
suspension. Each experimental condition was seeded in quadruplicate, and 
the FluoroBlok insert was incubated in normal growth conditions over 36 h to 
allow cells to migrate to the bottom chamber. Cell migration was estimated by 
measuring fluorescence of the cells on the bottom of the FluoroBlok 
membrane by exciting at 520 nm and reading at 580 nm in a 4 x 4 matrix at 
gain 2000.  
 
3.2.b.13 Generation of (AGR3) conditioned media 
 
To maximize accumulation of AGR3 protein in the medium, AGR3 
inducible 22Rv.1 cells were first pre-induced for 24 h with 5 µM Ponasterone 
in normal growth medium (10% FBS v/v, in RPMI 1640), then washed once 
with 1 x PBS before being grown for a further 24 h in serum-free medium with 
5 µM Ponasterone A. The same procedure was repeated in the absence of 
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Ponasterone A to generate serum free medium lacking AGR3 as control. This 
control serum-free medium was then supplemented with either EtOH or 5 µM 
Ponasterone A to generate control media. Both control media (with EtOH or 
just Ponasterone A) and AGR3 conditioned media were supplemented with 
10% FBS prior to use.  
 
3.2.c Protein methods 
 
3.2.c.1   Preparation of protein samples from cell lysates 
 
 Before lysis, cells were washed once with 1 x PBS and resuspended in 
a defined volume 1 x PBS prior to estimating cell concentration by counting 
with a hemocytometer (Fuchs Rosenthal, 0.200mm depth). After the number 
of cells to be lysed was calculated, cells were pelleted at 1200 rpm for no 
more than 3 min and the residual supernatant removed. A second 
centrifugation step of 1 min at 1200 rpm was carried out to remove all 
suspension solution from the vessel walls, and therefore ensure no additional 
unwanted volume in lysed cells. The pellet was then suspended in 2 x protein 
sample buffer (Tris-HCl 160 nM, 4% v/v SDS, 20% v/v Glycerol, 4% v/v 2-ß-
mercaptoethanol, and 0.01 w/v bromophenol blue). The volume of sample 
buffer used was calculated to lyse 4 x 104 cells with 1 µl of 2 x sample buffer. 
 
 
3.2.c.2   Separation of proteins by SDS-PAGE 
 
Gels of either 0.75 or 1 mm thickness were cast using the Mini-
PROTEAN 3 system (Bio-Rad, Munich, Germany). For most experiments, a 
12 % polyacrylamide separating gel was cast using a mixture of 2.2 ml of 
dH2O, 3 ml of 37% w/v acrylamide mix, 1.9 ml of 1.5 M Tris-HCl, 75 µl of 10% 
w/v SDS, 75 µl of 10% w/v APS (ammonium persulfate), and 5 µl of TEMED 
(N,N,N’,N’-tetramethylethylenediamine). After polymerization, an appropriate 
volume of stacking gel (2.75 ml of dH2O, 0.65 ml of 37% w/v acrylamide mix, 
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0.5 ml of 1.5 M Tris-HCl, 40 µl of 10% w/v SDS, 40 µl of 10% w/v APS 
(ammonium persulfate), and 4 µl of TEMED (N,N,N’,N’-
tetramethylethylenediamine) was cast over the polymerized separating gel, 
and shaped using 10-well or 15-well combs (Bio-Rad, Munich, Germany) of 
appropriate thickness. Electrophoresis was carried out with an appropriate 
volume of 1x Laemmli buffer (for 10x, 30.0 g of Tris-base, 144.0 g Glycine, 
10.0 g SDS dissolved in 1 l of dH2O, and diluted 1:10 also in dH2O), and 
constant 22.5 mA / 1 mm thick gel over 1.5 h, or until the dye front eluted off 
the bottom of the vertically set gel.  
 
 
3.2.c.3   Immunobloting of proteins (Western blot) 
 
SDS-PAGE resolved proteins were transferred to methanol-activated 
PVDF (polyvinylidene fluoride, Millipore, Schwalbach, Germany) membranes 
prior to immunobloting. Transfers were performed using a Mini Trans-Blot 
electrophoretic transfer cell (Bio-Rad, Munich, Germany) in transfer buffer 
consisting of (for 10x) 58.1 g of Tris-base, 29.3 g of Glycin, dissolved in dH2O, 
diluted 1:10 in dH2O and supplemented with 20% v/v methanol, and a 
constant 115 V at 4°C with constant mixing for 1.5-2 h. An alternative 
overnight transfer (8-16 h) used the same blotting buffer and a constant 40 V 
at room temperature. 
 After transfer completion, the membrane was blocked with appropriate 
blocking solution for 30 min – 1 h with gentle shaking, and subsequently 
incubated with primary antibody diluted in blocking solution for 1 h, or over 
night at 4°C. The membrane was then washed 3 times for 10 min each in 
washing buffer 1x TBS-T which was diluted 1:10 from 10x TBS (24.0 g of Tris-
base, 80 g of NaCl, and pH 7.6) and supplemented with 0.1% Tween 20 
detergent. Secondary antibody was carried out for 30 min to 1 h using the 
same blocking buffer as the primary antibodies with gentle shaking. 
Subsequently, the membrane was washed 3 times for 10 min in 1x TBS-T, 
and incubated with ECL (enhancer of chemioluminescence, Amersham, 
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Braunschweig, Germany) solution for 1 min, prior to exposure on Fuji Super 
RX 18x24 film (Ernst Christiansen GmbH, Planegg, Germany).  
 
3.2.c.4 Visualization of blotted proteins on membrane (staining with 
Coomassie blue) 
 
To visualize blotted proteins, PVDF membranes were stained with 
coomassie blue solution (45% v/v methanol, 10% v/v acetic acid, 0.01% w/v 
coomassie blue) for 30 min – 1 h at room temperature with gentle shaking. 
Subsequently, excess dye was washed off the membrane by incubating for 30 
min periods at room temperature with gentle shaking in destaining solution 
(45% v/v methanol, 10% v/v acetic acid). After adequate destaining, the 
membrane was rinsed with dH2O.  
 
3.2.d Bioinformatics methods 
 
3.2.d.1 Gene set enrichment analysis 
 
 Gene set enrichment analysis (GSEA) was conducted to analyze the 
patterns of differentially expressed genes. GSEA is a computational method 
that determines whether the differential expression of groups of genes 
between two different conditions is statistically significant 
(http://www.broad.mit.edu/gsea). Here, differences in the expression of a 
priori defined gene sets (i.e. a biological pathway) was identified by using 
GSEA. Enrichment of GO gene sets (gene ontology), which consists of 
groups of genes annotated by the same GO terms in the Molecular Signature 
Database (MSigDB) were analyzed against a fold-change ranked list of 1022 
genes. Due to the size of the gene list, all GO sets with less than 5 or more 
than 500 genes were excluded from analysis. Enrichment was computed by 
evaluating statistical significance against 1000 random permutations.  
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3.2.d.2 Chip-seq data analysis: read processing and peak calling 
 
Chip-seq data of LNCaP cells treated with either EtOH or 10nM R1881 
were obtained from [30] in fastq format. These files were uploaded on the 
main galaxy project server (https://usegalaxy.org/) and first quality filtered 
using the “filter by quality” tool, by discarding all reads where the quality of 
90% of reads was lower than 20. Reads were then mapped on hg19 (human 
genome version 19) using bowtie, and the resulting “SAM” format file was 
converted into the “BAM” format using Samtools 0.1.18. MACS (model based 
analysis of chip-seq) was used to identify binding sites, and the resulting BED 
file was converted to GFF format prior to visualizing peaks on the UCSC 
(University of California Santa Cruz) genome browser website.  
 
 
3.2.d.3 Graphing software and Statistics  
 
Throughout this study, statistical analysis was carried out using a 
students t-test unless otherwise specified. Data was visualized in graphs 
generated using the R environment (3.0.1), with the ggplot2 graphing package 
(0.9.3.1). Heatmaps were generated using the MEV (multi-experiment viewer) 
version 4.8.  
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4. RESULTS 
 
 
4.1 AGR3 expression is elevated in late-stage PCa patients and the VCaP 
cell line 
 
One of the unmet challenges of prostate cancer is the ability to 
distinguish between indolent and aggressive disease. Currently, aggressive 
prostate cancer diagnosis relies in part on the estimated Gleason score, 
which rates aggressiveness based on deviation from healthy prostate tissue 
morphology on a scale of 1 (indolent) to 10 (most aggressive). Early 
recognition of aggressive disease requires better characterization of 
supporting molecular mechanisms. Recent studies have revealed several 
disregulated genes in prostate cancer whose expression correlates positively 
with an aggressive disease phenotype [86-88]. AGR3 was recently detected 
as part of a set of genes upregulated in prostate cancer [85]. The present 
study sought to confirm AGR3 upregulation in prostate cancer, and to 
determine whether AGR3 expression correlates with aggressive disease.  
AGR3 gene expression values and matching Gleason scores were 
obtained from the Oncomine database, which is a repository of genome-wide 
gene expression values and associated clinical metadata (e.g. Gleason score) 
of cancer patients. Any datasets (i.e. group of patient data) lacking normal 
tissue samples, necessary to confirm AGR3 upregulation in prostate cancer, 
were excluded from analysis. Within each dataset, patient samples were 
subdivided into normal (healthy prostate), Gleason 1-7 (low – intermediate 
disease), and Gleason 8-10 (aggressive disease) categories. Datasets with 
fewer than 5 samples in any of these categories were deemed to contain an 
insufficient number of datapoints to establish a trend, and were omitted. 
AGR3 expression values were plotted against these three categories in the 
remaining datasets (Figure 3A), and statistical significance of differences 
estimated using a one-tailed t-test.  
In both datasets tested, AGR3 expression in Gleason 1-7 and Gleason 
8-10 samples was significantly higher than in normal samples, confirming the 
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previous observations of AGR3 upregulation in prostate cancer [85]. The 
Taylor, et al. dataset showed significant difference between Gleason 1-7 and 
8-10 categories, with the latter containing the highest expression values of 
AGR3. Similarly, Vanaja, et al. contained the highest AGR3 expression values 
in the Gleason 8-10 category, but yielded only a near-significant difference 
(p=0.094) in the Gleason 1-7 v.s. 8-10 comparison. Together, these results 
confirm a previous report of AGR3 upregulation in prostate cancer, and 
suggest a possible association between AGR3 mRNA expression and 
aggressive (Gleason 8-10) disease.  
 
 
 
 
Figure 3. AGR3 expression in prostate cancer patients cell lines.            
(A) Log2 transformed, median centered AGR3 expression values obtained from two 
Oncomine datasets (www.oncomine.org, studies [89] and [13]) were plotted against normal, 
low-moderate (1-7), and high (8-10) Gleason scores. Bracketed numbers in the x-axis labels 
indicate the number of patient samples in each category. The horizontal line within the box 
indicates the median value. The upper and lower limits of the box indicate the bottom of the 
1st and 3rd quartiles (q1 and q3). The vertical lines indicate standard deviation, while round 
dots above and below each box indicate outliers calculated as follows: below the box = q1 – 
1.5(q3-q1), and above the box = q3 + 1.5(q3-q1). A one-tailed t-test was used to evaluate 
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significant differences between patient categories (* p<0.05).  
(B) AGR3 mRNA expression in a panel of PCa cell lines was estimated by PCR (polymerase 
chain reaction) in cDNA samples reverse transcribed from total RNA using AGR3 primers and 
ß-actin specific primers as control.     
(C) AGR3 protein expression in a panel of PCa cell lines was estimated by immunobloting 
whole-cell lysates with AGR3 and α-tubulin antibody as control.   
 
 
To study AGR3 in prostate cancer, AGR3 expression was first 
determined at the mRNA level using PCR in cDNA reverse transcribed from 
total RNA extracted from a panel of prostate cancer cell lines, as well as 
BPH1 (benign prostatic hyperplasia derived) and PNT2 (normal prostate 
epithelium derived) cell lines. (Figure 3B). The highest level of AGR3 mRNA 
was detected in both DuCaP and VCaP cells, while no expression could be 
detected in any of the other cell lines. To confirm this result, AGR3 protein 
expression was examined in whole-cell lysates from the same panel of cell 
lines by immunobloting with either AGR3 or α-tubulin antibody as control. 
AGR3 protein expression was detected in VCaP, and faintly in DUCaP cells, 
confirming expression results obtained at the mRNA level. The VCaP cell line 
was chosen for further knockdown studies because of higher AGR3 
expression at both protein and mRNA level.  
 
 
4.2 Endogenous AGR3 enhances VCaP cell proliferation  
 
The most distinct feature of prostate malignancy is increased cell 
proliferation in the epithelium. To determine whether AGR3 influences 
prostate cancer cell proliferation, its expression was suppressed in VCaP cells 
using lentiviral-mediated transduction of expression vectors containing an 
anti-AGR3 shRNA sequence. Three different shAGR3 sequences were used 
to generate stable AGR3-knockdown in VCaP cells (lanes 4-6, Figure 4B), 
while a non-target shRNA sequence was used to generate control cells (lanes 
1-3, Figure 4B). Suppression of AGR3 protein was confirmed by 
immunobloting whole-cell lysates of these 6 clones with either AGR3 or ß-
actin antibody as control (Figure 4B). The effect of AGR3 on prostate cancer 
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cell proliferation was determined using the [3H]-thymidine incorporation assay, 
which measures cell proliferation indirectly by estimating the amount of new 
DNA synthesis.  
 
 
	  
 
 
Figure 4. AGR3 enhances VCaP cell proliferation.  
(A) AGR3 influence on VCaP cell proliferation. Stable control (C1-3) and AGR3-knockdown 
(KD1-3) clones were allowed to proliferate in the presence 1µCi (~37kBq) of 5’-[3H] thymidine 
(specific activity of 20-30 Ci (0.74-1.11 TBq)/mmol). After 12 h, cells were harvested on a filter 
matt that was soaked in scintillation counting cocktail and the CPM (counts per minute) read 
on a scintillation beta counter. To minimize cell counting and seeding errors, the number of 
cells seeded at the beginning of the experiment was determined by incubating for 1 h with 
Celltiter-Blue reagent followed by quantification with a spectrophotometer (excitation/emission 
560/590 nm). CPM values were normalized to Celltiter-Blue fluorescence values, and 
significance was estimated using a one-tailed t-test. (* p<0.05, ns = not significant, mean ± 
SD, n = 3)   
(B) AGR3 protein expression in VCaP cells used in (A). Whole-cell lysates from three control 
clones (lanes 1-3), obtained using a non-target shCon sequence, and three AGR3-
knockdown clones (lanes 4-6), each generated from a unique anti-AGR3 shRNA sequence, 
were immunoblotted with AGR3 and ß-actin antibody as control.    
(C) To rescue the effect observed in (A), AGR3 expression was restored in AGR3-knockdown 
cells by stably transfecting with AGR3 cDNA (lane 4) or empty vector (lane 3) as control. 
Control VCaP cells, stably expressing a non-target shRNA sequence, were also transfected 
with empty vector (lane 1) or AGR3 cDNA (lane 2). Proliferation of these cells was determined 
using the conditions described in (A). Significance was estimated using a one-tailed t-test. (* 
p<0.05, ns = not significant, mean ± SD, n = 3)  
(D) AGR3 expression was determined from whole-cell lysates of cells generated in (C) by 
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immunobloting with either AGR3 or ß-actin antibody as control.  
 
In this assay, cells are exposed to [3H]-thymidine (a tritium labeled 
nucleotide), which is incorporated into newly synthesized DNA rendering it 
quantifiable by measuring radioactivity with a beta scintillation counter. 
Control and AGR3-knockdown VCaP cells were incubated with 1 µCi 
(~37kBq) of 5’-[3H]-thymidine for 12 h before determining the amount of [3H]-
thymidine incorporated. These same cells were also incubated with 20 µl of 
Celltiter-Blue reagent for 1 h. The Celltiter-Blue reagent (resazurin) is 
metabolized by viable cells to resorufin, which fluoresces at 590 nm and 
indicates the number of viable cells present. Proliferation was determined by 
normalizing DNA radioactivity measured in CPM (counts per minute) to the 
fluorescence at 590 nm (Celltiter-Blue measurement) obtained at the 
beginning of the experiment. This assay revealed reduced cell proliferation in 
cells with a stable AGR3-knockdown when compared to controls, indicating 
that endogenous AGR3 sustains prostate cancer cell proliferation (Figure 4A).  
To confirm this result, the ability of AGR3 to rescue the reduced 
proliferation resulting from its suppression was tested by restoring AGR3 
expression in the AGR3-knockdown VCaP cells. After transfecting with an 
AGR3 cDNA-containing vector (lanes 2 and 4, Figure 3D) or empty vector as 
control (lanes 1 and 3, Figure 3D), AGR3 protein expression was determined 
in whole-cell lysates by immunobloting with either AGR3 or ß-actin antibody 
as control. To determine proliferation of these cells, the [3H]-thymidine 
incorporation assay was used as previously described. Restoring AGR3 
expression in AGR3-knockdown cells resulted in significantly increased 
proliferation when compared to controls (compare 3 and 4 in Figure 4C). In 
addition, cells with a stable knockdown of AGR3 also showed significantly 
decreased proliferation (compare 1 and 3 in Figure 4C). However, 
overexpression AGR3 beyond endogenous levels did not significantly 
increase proliferation (compare 1 and 2 in Figure 4C), suggesting that near-
endogenous AGR3 levels are sufficient to enhance proliferation in VCaP cells. 
Together, these experiments suggest a positive role for AGR3 in prostate 
cancer cell proliferation.  
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4.3 Overexpression of AGR3 enhances prostate cancer cell proliferation 
 
To determine whether the effect of AGR3 on cell growth is limited to 
VCaP cells, AGR3 protein was stably expressed in three different AGR3-
negative prostate cancer cell lines, namely 22Rv.1, LNCaP, and PC-3. To 
estimate AGR3 expression, whole-cell lysates from control (C1 and C2) and 
AGR3-expressing cells (#1 and #2) were immunoblotted with either AGR3 or 
ß-actin antibody for each cell line (Figure 5A, 5C, 5E). [3H]-thymidine 
incorporation proliferation assays revealed that in these cells moderate AGR3 
levels enhanced cell proliferation, but high expression of AGR3 either did not 
alter (LNCaP and PC-3 cells, #2 in Figure 5D and 5F), or reversed this effect 
(22Rv.1 cells, #2 in Figure 5B). These results indicate a positive influence of 
AGR3 on cell proliferation and suggest that this effect is not cell-type specific. 
However, since not all clones showed increased proliferation, this result may 
also stem from differences between individual clones (i.e. clonal variation). 
Alternatively, given that proliferation was reduced or unchanged only in clones 
with high AGR3 expression, this effect may be due to forced expression of 
artificially high amounts of AGR3.  
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Figure 5. AGR3 enhances proliferation in 22Rv.1, LNCaP, and PC-3 cells. 
(A) AGR3 protein expression in 22Rv.1, LNCaP (C), and PC-3 (E) cells was detected in two 
control (C1 and C2) and two AGR3-expressing (A1 and A2) clones by immunoblotting whole-
cell lysaes with AGR3 or ß-actin antibody as control.  
(B) Proliferation of control, low, and high AGR3-expressing 22Rv.1, LNCaP (D), or PC-3 (F) 
clones was estimated as described previously (Figure 4B). Briefly, 103 cells were incubated 
with either 100 µl of normal growth medium containing 1 µCi (~37kBq) for 12 h, or with 100 µl 
and 20 µl of Celltiter-Blue reagent for 1 h under nomral gorwth conditions. CPM values from 
the [3H]-thymidine incorporation were nomralized to 595 nm fluoresence values from 
metabolized Celltiter-Blue reagent. Significance was computed by comparing each AGR3 
expression clone (low and high) with the two control clones, using a one-tailed t-test. (* 
p<0.05, ns = not significant, mean ± SD, n = 3) 
 
To address these possibilities, 22Rv.1 cells were used to generate a 
cell system in which AGR3 expression is inducible. One of the main 
advantages of the inducible system is the ability to compare gene expression 
within a similar genetic background (i.e. in the same clone). To generate the 
inducible system, cells were first transfected with the Rheo activator/receptor 
(pNEB-R1 plasmid) and selected with using G418. Cells with stable pNEB-R1 
expression were isolated and transfected with the pNEBR-X1 Hygro plasmid, 
which expresses the AGR3 mRNA under the control of the Rheo 
activator/receptor. Stable expressers were selected by growing cells in 
hygromycin B. Once both plasmids were stably expressed, AGR3 expression 
was induced by stimulating the Rheo activator/receptor with Ponasterone A, 
an Ecdysone steroid hormone analog that regulates metamorphosis in 
Drosophila melanogaster [90].  
One Control and three AGR3 inducible clones (A, B, and C), differing in 
their maximal AGR3 expression level, were isolated and characterized by 
treating with either 5 µM of Ponasterone A (to achieve maximal expression) or 
EtOH as control. AGR3 protein expression was monitored with western 
blotting every 24 h for 6 days after induction (Figure 6A-D). AGR3 expression 
in T47D was used as a reference to compare maximal AGR3 protein 
expression between clones. After application of 5 µM Ponasterone A, Clone A 
yielded the highest level of AGR3 expression, followed by clone B, and then 
clone C which expressed AGR3 at only moderate levels. Maximal expression 
was detected 48 h after treatment and steadily declined over the next 96 h 
(Figure 6A). As expected, treatment of the Control clone with Ponasterone A, 
or treatment of any clone with EtOH, did not result in AGR3 expression. 
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Figure 6. Inducible AGR3 overexpression in 22Rv.1 cells leads to contrasting effects on 
growth dependent on AGR3 expression level.  
(A) Characterization of 22Rv.1 cells with inducible AGR3 expression. In AGR3 inducible 
22Rv.1 cells, AGR3 expression was induced by activating the stably expressed Rheo 
activator/receptor with either 5 µM Ponasterone A. An equal amount of EtOH was applied as 
control. AGR3 expression was monitored at the protein level by obtaining whole-cell lysates 
every 24 h over 6 days, and immunobloting with AGR3 and ß-actin antibodies as control. A 
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constant amount of T47D breast cancer cell lysate, which express high levels of endogenous 
AGR3, was included as a reference to compare maximal AGR3 expression between inducible 
22Rv.1 clones. 
(B) Expression level determines the effect of AGR3 on 22Rv.1 cell proliferation. The 
proliferation of Control, and Clones A-C was measured by pre-treating 1 x 103 cells for 24 h 
with 5 µM of Ponasterone A or EtOH as control in normal cell culture growth medium before 
supplementing with 1 µCi of 5’- [3H]-thymidine for 12 h or 20 µl of Celltiter-blue reagent for 1h. 
Proliferation values were computed by normalizing CPM counts to absorbance at 595 nm for 
each sample. Significance was estimated using a one-tailed t-test. (* p<0.05, ns = not 
significant, mean ± SD, n = 3). 
 
 
To estimate the effect of AGR3 expression on proliferation using the 
inducible system, an equal number of cells from Control and AGR3-inducible 
clones (A, B, and C) were treated with either 5 µM Ponasterone A or an equal 
volume of EtOH as control under normal growth conditions for 24 h before 
carrying out a 12 h [3H]-thymidine incorporation assay. Proliferation of the 
Control clone was not affected by the application of Ponasterone A indicating 
the absence of any pleiotropic effects from ligand application (Figure 6B). 
Proliferation of clones A and B (high expressers) was reduced, while 
proliferation of clone C (moderate expresser) was enhanced. Moreover, Clone 
A, which expresses the highest amount of AGR3 upon induction, also showed 
the greatest reduction in proliferation. Together, these results provide 
additional evidence of the positive effect of AGR3 on prostate cancer cell 
proliferation, and indicate that the reduction of proliferation observed may be 
due to artificially high levels of expression.  
Another aspect of the inducible system is the ability to tune the 
expression of the gene of interest by changing the amount of inducing ligand 
(Ponasterone A) applied. To show that moderate AGR3 levels enhance 
proliferation in a clone independent manner, different levels of AGR3 
expression were induced by pre-treating Control and Clone A cells with either 
0.5, 1, 2.5 and 5 µM of Ponasterone A or EtOH as control over 24 h. To 
monitor expression level, a fraction of cells from each treatment was used to 
generate whole-cell lysates immunoblotted with AGR3 or ß-actin antibody as 
control (Figures 7A and 7B). 
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Figure 7. Modulating AGR3 expression levels alters 22Rv.1 cell proliferation.   
(A) Whole-cell lysates obtained from Control and Clone A cells treated with a range of 
Ponasterone A concentrations (0.5, 1, 2.5, and 5 µM) or EtOH as control for 24 h were 
immunoblotted with either AGR3 or Vinculin antibody as loading control.  
(B) Control and Clone A cells pre-treated for 24 h with a range of Ponasterone A 
concentrations (0.5, 1, 2.5, and 5 µM) or EtOH were used to carry out a [3H]-thymidine 
proliferation assay. Briefly, 1 x 103 cells were grown in normal growth medium supplemented 
with either 1 µCi of [3H]-thymidine for 12 h or 20 µl of Celltiter-Blue reagent for 1 h. 
Proliferation values were computed by normalizing CPM counts to absorbance at 595 nm for 
each sample. Significance was estimated using a one-tailed t-test. (* p<0.05, ns = not 
significant, mean ± SD, n = 3).   
 
 
AGR3 expression was lowest at 0.5 µM of Ponasterone A, and 
increased gradually to maximal levels when induced with 5 µM of ligand. No 
AGR3 expression could be detected in Control cells treated with Ponasterone 
A, or any cells treated with EtOH. To measure proliferation of the pre-induced 
cells, a [3H]-thymidine incorporation assay was carried out for 12 h. 
Ponasterone A treatment did not affect proliferation at 0.5 or 2.5 µM, 
decreased proliferation at 5 µM, but enhanced it at 1 µM of ligand (Figure 7D), 
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confirming that AGR3 enhances proliferation, and demonstrating that 
induction of abnormally high amounts of this protein abrogates and even 
reverses this effect.   
To further confirm this effect, an alternative long-term assay was used 
to measure cell proliferation in the AGR3-inducible 22Rv.1 cell system. In the 
Celltiter-Blue proliferation assay, conversion of the fluorescent reagent 
resazurin into to resorufin by metabolically active cells provides an indirect 
means of estimating cell number. The conversion rate of this reaction 
correlates linearly with the number of cells resazurin is exposed to, and 
indirectly reveals cell proliferation. Inducible Clones A, B and C, as well as the 
Control clone were treated with 5 µM Ponasterone A or EtOH as control and 
used in a long-term proliferation assay carried by sampling at 1, 3, and 5 days 
after induction.   
 
 
 
Figure 8. Long-term effect of AGR3 expression in inducible 22Rv.1 cells.   
1 x 103 cells were treated with 5 µM of Ponasterone A or EtOH as control, and incubated 
under normal growth conditions. 1, 24, 72, and 120 h after seeding, cells were supplemented 
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with 20 µl of Celltiter-Blue reagent which was allowed to metabolize for 1 h prior to reading 
the converted dye signal at 595 nm with a spectrophotometer. Values from 24, 72, and 120 h 
were normalized to those obtained at 1 h after seeding at the beginning of the experiment. 
Significance was estimated using a one-tailed t-test. (* p<0.05, ns = not significant, mean ± 
SD, n = 3). 
 
 
In this assay, Clones A and B showed dramatically reduced 
proliferation by day 5, while Clone C showed significantly increased 
proliferation confirming previous results obtained using the [3H]-thymidine 
based assay (Figure 8). The Control clone did not show any significant 
differences between EtOH and Ponasterone A treatments suggesting no 
adverse effects from long term exposure to ligand.  
Together, the results of the [3H]-thymidine incorporation and Celltiter-
Blue assays indicate a positive role for AGR3 in prostate cancer cell 
proliferation. In subsequent experiments, only 22Rv.1 cells stably expressing 
proliferation-enhancing levels of AGR3 were used.  
 
 
4.4 Secreted AGR3 enhances prostate cancer cell proliferation 
 
The AGR3 protein contains an N-terminal signal peptide that targets it 
for secretion. Its close homolog, AGR2, has a similar signal peptide and is 
secreted to the extracellular space where it participates in a diverse set of 
functions [59]. For example, extracellular nAG, an AGR2 homolog in adult A. 
maculatum, is able to induce proliferation of blastema cells in culture, while 
extracellular H. sapiens AGR2 plays a role in adhesion and migration [35, 46, 
78, 82]. Given the extracellular roles of AGR gene homologs, this study 
sought to find out whether AGR3 is also a secreted protein, and if so, whether 
extracellular AGR3 contributes to prostate cancer cell proliferation.  
To find out whether AGR3 is a secreted protein, 22Rv.1 cells were 
transiently transfected with either empty or AGR3 cDNA-containing vector. 
Untransfected 22Rv.1 cells were included as an additional control. After 24 h 
of transfection, medium was collected and medium protein and matching 
whole-cell lysate samples were immunoblotted with AGR3 and ß-actin 
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antibody as control. Empty vector and untransfected control cells displayed no 
detectable AGR3 protein, which was detected only in the lysate and medium 
of cells transfected with the AGR3 cDNA-containing vector (Figure 9A). The 
presence of this protein in the medium suggests that, similar to AGR2, AGR3 
is also a secreted protein. 
AGR3-conditioned medium was generated and used to study the role 
of extracellular AGR3 in prostate cancer cell proliferation. The amount of 
AGR3 in AGR3-conditioned media was optimized using in 22Rv.1 inducible 
cells. AGR3 expression was induced in Clone A 22Rv.1 cells (AGR3 
inducible) using a range of different (0.1, 0.5, 1.0, 2.5, 5.0 µM) Ponasterone A 
concentrations or EtOH as control. Secreted protein samples were obtained 
by precipitating medium proteins with 10 µl of Strataclean resin, and eluting 
with Laemmli buffer. Together with corresponding whole-cell lysates, these 
samples were immunoblotted with AGR3 and α-tubulin as control. Similarly 
obtained secreted and whole-cell lysate T47D samples were included to 
compare the amount of secreted AGR3 protein to that secreted by T47D. 
Induction of AGR3 protein was detected in cells treated with 2.5 and 5 µM 
Ponasterone A, and secretion was observed for the same set of samples 
(Figure 9B). The highest level of secreted AGR3 protein was observed in cells 
treated with 5 µM Ponasterone A (Figure 9B). Together, these results 
indicated that induction of AGR3 protein in Clone A cells with 5 µM 
Ponasterone A for 24 h was optimal to generate AGR3-conditioned medium.  
To find out whether secreted AGR3 protein plays a role in proliferation, 
AGR3-conditioned and control media were generated using AGR3-inducible 
22Rv.1 cells. Clone A cells were pre-induced for 24 h with 5 µM Ponasterone 
A in 10% FBS v/v (fetal bovine serum) growth medium to generate an initial 
amount of AGR3 expression. These cells, were then washed with 1xPBS 
(phosphate buffered saline) to remove any residual FBS and grown for a 
further 24 h in serum-free medium with 5 µM Ponasterone A to induce 
additional AGR3 expression and secretion (3), or without as control. The latter 
medium, which did not include Ponasterone A, and therefore contained no 
secreted AGR3, was used to generate control media (1 and 2) by adding 
either EtOH or 5 µM of Ponasterone A respectively (Figure 9C).  
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Figure 9. Secreted AGR3 has a moderate effect on prostate cancer cell growth. 
(A) AGR3 protein is secreted by prostate cancer cells. 22Rv.1 cells were transiently 
transfected for 24 h with empty or AGR3 cDNA as control. An additional sample of non-
transfected (no trfc.) cells was included as control. After 24 h, medium protein samples were 
obtained by precipitating medium proteins Strataclean resin followed by elution in Laemmli 
sample buffer. Secreted and whole-cell lysate protein samples were immunoblotted with 
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AGR3 and ß-actin antibody as control.          
(B) Optimization of AGR3 protein concentration in conditioned media. AGR3-inducible Clone 
A (22Rv.1) cells were treated for 24 h with a range of Ponasterone A concentrations (0.1, 0.5, 
1, 2.5, and 5 µM) or EtOH as control. Secreted protein samples were obtained by 
precipitating medium proteins using Strataclean resin followed by elution in Laemmli sample 
buffer. Secreted and whole-cell lysate protein samples were immunoblotted with AGR3 and α-
tubulin antibody as control. T47D secreted or whole-cell lysate protein samples were 
immunoblotted in parallel as positive control.  
(C) The strategy used to generate control (1 and 2) and AGR3-conditioned media (3). To 
maximize accumulation of AGR3 protein in the medium, Clone A 22Rv.1 cells were first pre-
induced for 24 h with or without 5 µM Ponasterone in normal growth medium (includes 10% 
v/v FBS). Cells were then washed once with 1 x PBS and grown for a further 24 h in serum-
free medium with or without 5 µM Ponasterone A. Serum-free medium without Ponasterone 
A, and therefore without AGR3, was supplemented with EtOH or 5 µM Ponasterone A to 
generate control media 1 and 2 respectively.   
(D) Detection of AGR3 protein in conditioned media. Medium proteins in media 1, 2, and 3 
were detected as described in (A). Medium and matching whole-cell lysate protein samples 
were immunoblotted with AGR3 antibody as control. After AGR3 detection, proteins trapped 
on the PVDF membrane were stained with coomassie blue dye to show equal loading of 
samples.  
(E) 22Rv.1 Control clone (non-inducible) and DU145 cells were grown using conditioned 
media 1, 2, and 3 for 48 h prior to a 12 h [3H]-thymidine incorporation based proliferation 
assay carried as described previously. Significance was estimated using a one-tailed t-test. (* 
p<0.05, ns = not significant, mean ± SD, n = 3). 
 
 
To confirm AGR3 presence in the medium, secreted protein samples 
from media 1-3 were obtained by precipitating medium proteins with 
Strataclean resin, and eluting in Laemmli sample buffer. Subsequently, these 
samples were immunoblotted with AGR3 antibody. As expected, AGR3 was 
readily detected in medium 3, but not in control media 1 and 2 (Figure 9D).	    
Conditioned media 1-3 where used to grow Control clone 22Rv.1 cells 
that do not express AGR3 after Ponasterone A application. To rule out any 
influence of endogenous cellular AGR3, DU145 prostate cancer cells, which 
have no detectable AGR3 expression at the protein level, were also included 
in this experiment. After 48 h of growth in either control (1 and 2) or AGR3-
conditioned (3) media, 22Rv.1 and DU145 cells reseeded for a [3H]-thymidine 
incorporation proliferation assay. Proliferation was calculated by normalizing 
CPM values obtained after an additional 12 h of growth in conditioned media 
1-3 supplemented with 1µCi of 5’-[3H]-thymidine to fluorescent values 
measured at 590 nm (Celltiter-Blue) obtained at the beginning of the [3H]-
thymidine treatment. Proliferation of Control clone 22Rv.1 cells was slightly 
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but significantly increased after growth in AGR3-conditioned medium (Figure 
9E). Furthermore, AGR3-negative DU145 cells showed a more pronounced 
increase in proliferation after treatment with AGR3 conditioned media, 
suggesting that a portion of AGR3-mediated increase in cell proliferation may 
be attributable to secreted AGR3 protein. Together, these results confirm 
secretion of a fraction of AGR3 protein, which may play a role in prostate 
cancer cell proliferation. 
 
 
4.5 AGR3 expression modulates migration and adhesion of prostate 
cancer cells  
 
In addition to increased proliferation, cancer cells adhere to substrate 
and have a higher tendency to migrate than non-cancer cells. Since AGR3 
expression was found to correlate with advanced prostate cancer (Gleason 
scores 8-10) in which cells commonly spread beyond their tissue of origin, a 
possible role of AGR3 was hypothesized in cell migration.  
Migration of previously generated AGR3 knockdown clones (see Figure 
4B) was assessed using the Boyden chamber assay, in which cells seeded on 
the upper chamber of a two a two-chamber setup migrate across a separating 
membrane toward a chemo attractant present in the lower chamber. In this 
iteration of the Boyden chamber assay, cell migration was tracked by 
measuring the fluorescence of cells stained with Vybrant DiI (a non-toxic 
lipophilic cell-membrane dye used to stain live cells) on the lower-chamber 
facing side of the membrane using a spectrophotometer. To reach the lower 
chamber, cells sense the normal growth medium (chemo attractant) and then 
traverse the membrane through 8 µm (diameter) pores.  
In this experiment, stained cells were suspended in serum-free medium 
and allowed to migrate toward normal cell growth medium (containing 10% v/v 
FBS) over 36 h under normal cell growth conditions. The amount of stained 
cells detected on the lower-chamber facing side of the membrane was visually 
inspected using a fluorescent microscope, and then quantified by  
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Figure 10. AGR3 affects the migration and 
adhesion of VCaP cells.   
(A) Migration of control (C1-3) and AGR3-
knockdown (KD1-3) VCaP cells. Vybrant DiI 
stained cells were seeded in quadruplicate in 
the upper chamber of 24-well BD cell culture 
inserts (Boyden chambers). Cells were 
allowed to migrate for 36 h toward growth 
medium supplemented with 10% v/v FBS. The 
number of migrated cells was estimated by 
measuring fluorescence at 495 nm. Significant 
differences were estimated using a one-tailed 
t-test. (* p<0.05, mean ± SD, ns = not 
significant, n = 3)  
(B) Substrate specific adhesion of control (C1-
3) and AGR3-knockdown (KD1-3) VCaP cells. 
Control or AGR3-knockdown cells were 
suspended in serum free medium and seeded 
in fibronectin or Collagen I coated cell culture 
plates under normal growth conditions. 
Unhindered binding was measured by seeding 
the same number of cells, suspended in 
normal growth medium in uncoated wells. 1 h 
after seeding, cells were fixed with methanol, 
and stained with crystal violet. The dye 
trapped in cells was extracted with acetic acid 
and quantified by measuring absorbance at 
595 nm. Substrate-specific adhesion (i.e. 
substrate specificity) was determined by 
expressing substrate coated adhesion values 
as a percentage of unhindered adhesion 
values. (* p<0.05, mean ± SD, ns = not 
significant, n = 3)  
 
 
 
measuring and averaging fluorescence 
at 9 different locations arranged in a 3 
x 3 matrix in each well. The 
fluorescence of cells remaining in the 
upper chamber is blocked from detection by the membrane, and does not 
contribute to the detected signal. To minimize error due to cell seeding, the 
fluorescence of a sample of stained cell suspension from each clone was 
quantified at the beginning of every experiment, and used subsequently to 
normalize migration values. In this experiment the number of cells migrating to 
the bottom chamber for VCaP cells with a stable AGR3 knockdown (KD1-3) 
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was lower than that of controls (C1-3), indicating decreased VCaP cell 
migration in the absence of AGR3 (Figure 10A).  
Cell migration depends on efficient reorganization of cell adhesion, a 
process that includes cell-substrate (extracellular matrix) interactions [91]. To 
determine whether reduced migration was associated with altered cell 
adhesion, the same VCaP cells, with or without a stable AGR3 knockdown, 
were assayed for their ability to adhere to extracellular matrix substrate 
proteins such as fibronectin and collagen I. Substrate affinity was estimated 
by plating cells in collagen I or fibronectin coated culture dishes blocked with 
heat denatured BSA to prevent any direct adhesion of cells to plastic. Cells 
were suspended in either serum-free medium and seeded in substrate-coated 
wells, or normal growth medium and seeded in uncoated wells to estimate 
unhindered adhesion rates. Unattached cells were removed by washing with 
1xPBS prior to fixing with methanol and staining with crystal violet dye. The 
trapped crystal violet was subsequently extracted with acetic acid from 
attached cells and quantified by measuring absorbance at 595 nm. Substrate 
specific adhesion (i.e. to collagen I or fibronectin) was quantified by amount of 
cells attached to substrate-coated wells (specific adhesion) expressed as a 
percentage of cells attached to uncoated wells (unhindered adhesion). 
Compared to controls, AGR3-depleted VCaP cells showed reduced binding to 
both fibronectin and collagen I, indicating impaired cell interaction with key 
components of the extracellular matrix (Figure 10B, upper and lower chart).  
Together, these results indicate that AGR3 may play a role in prostate 
cancer cell migration by modulating cell adhesion.   
 
4.6. AGR3 suppression results in increased Lumican mRNA expression  
 
To characterize the mechanism of action of AGR3, data from a 
genome-wide gene expression experiment comparing control and AGR3-
depleted VCaP cells was analyzed. AGR3 suppression in previously 
generated control and AGR3-knockdown VCaP clones was confirmed at the 
protein level by immunobloting whole cell lysates with AGR3 or α-tubulin as 
control, and at the mRNA level through qPCR (quantitative polymerase chain 
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reaction) with cDNA template reverse transcribed from total RNA obtained 
from the same cells  (Figure 11A).  
Subsequently, total RNA samples from a single sample of each shCon 
and shAGR3 were extracted, reverse transcribed to cDNA, and applied to 
Human Genome U133 Plus 2.0 array chips by Dr. L. Klein-Hitpass 
(Universität Duisburg-Essen, Essen, Germany) who used the MAS 5.0 
(Affymetrix® Microarray Software suite 5.0) software to generate gene 
expression values and associated detection p-values, as well as fold-change 
differences between this pair of samples. Given that only one sample was 
analyzed from shCon and shAGR3 cells, the list differentially regulated genes 
was filtered on the basis of detection and expression fold-change p values 
(caption, Figure 11B) produced by the MAS 5.0 software that compares probe 
sets (11 pairs of 25-nucleotide long match and mismatch oligomers) for each 
gene.  
Furthermore, reduction in experimental noise was sought by excluding 
from analysis a minority of genes with expression values below 330 units in 
both samples (over 15 genes were selected for qPCR validation and 330 is 
the lowest expression value of a successfully validated difference in gene 
expression). The remaining 1022 (out of 3240) genes were arranged 
according to phenotype (i.e. “upregulated” and “downregulated” after AGR3 
suppression), ranked based on expression fold-change values (shAGR3 vs. 
shCon), and visualized in red-yellow (expression value) and red-green (fold-
change) heatmaps (Figure 11B).  
 To extract biological information on AGR3 function, the ranked 1022 
gene list established in the previous step (Figure 11B) was used to compute 
GO (gene ontology) gene set enrichment analysis using the GSEA 2.0 (gene 
set enrichment analysis) desktop software. GSEA computes enrichment 
based on the distribution of genes from a gene set (e.g. a GO gene set) along 
a ranked gene list (here the 1022 genes) [92]. GO gene set enrichment was 
determined according to p value. The gene list in Figure 11B contained 21 
significantly enriched GO gene sets (p values of less than 0.05) that broadly 
describe changes in developmental, neurological, and extracellular matrix 
related processes (Figure 11C).  
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Figure 21. Genome-wide expression analysis of AGR3 knockdown in VCaP cells 
reveals overrepresentation of extracellular matrix and developmental processes.  
(A) AGR3 mRNA expression of control (shCon) and AGR3-knockdown (shAGR3) cells used 
in genome-wide expression analysis experiment. Relative AGR3 mRNA expression was 
determined using qPCR in cDNA reverse transcribed from the total RNA of control and 
AGR3-knockdown cells. (mean ± SD, n = 3) 
(B) Whole cell lysates from control or AGR3-depleted VCaP cells used in genome-wide 
expression analysis experiment were immunoblotted with AGR3 and α-tubulin as control.  
(C) Genome wide-gene expression changes as a result of AGR3 depletion in VCaP cells. A 
Human Genome U133 Plus 2.0 Array chip was used hybridize cDNA reverse transcribed from 
RNA of control and AGR3-knockdown VCaP cells after 48 h of growth in medium 
supplemented with 3% v/v (charcoal-stripped calf serum) and EtOH for 24 h. This treatment 
was performed as part of an experiment designed to investigate androgen regulation in VCaP 
cells. Probe intensities were converted to expression values, fold-change ratios, and 
associated change p-values using the MAS5 algorithm implementation of the Affymetrix 
software suite. Genes with a detection p-value less than 0.05 in both samples were included 
in this analysis. After carrying out the shAGR3 treatment vs. shCon comparison, all genes 
with fold-change p-values greater than 0.0001 were excluded from further analysis. In 
addition, a minority of genes with signal values below 330 units in both samples, deemed to 
be too low to bear biological significance, were removed from the fold-change ranked list of 
genes. The 330 cutoff value was determined after qPCR validation of over 15 genes. 330 is 
the lowest microarray derived expression value of a successfully validated difference in gene 
expression using qPCR.  The remaining 1022 out of 3240 genes were ranked according to 
fold change on the shAGR3 v.s. shCon comparison and visualized on a red-green heatmap, 
while matching raw gene expression values were visualized on the adjacent red-yellow 
heatmap.  
(D) GSEA was carried out using the GO term set (category 5 on the MSigDB) of the fold-
change ranked list of genes from (B). GSEA was performed against a background of 1000 
random GO term (gene sets) permutations using a weighted statistic. In addition, all GO 
terms with less than 5 or more than 500 genes were omitted from analysis. P-values in red 
text indicate terms enriched in downregulated genes of the shAGR3 v.s. shCon comparison. 
Terms highlighted with a gray background were used to carry out leading-edge analysis (i.e. 
find the top genes driving the enrichment of these terms, see Figure 12A). 
 
 
 
Given that processes involving the extracellular matrix are related to 
cell migration and adhesion, the present study focused on the 5 extracellular 
matrix related GO gene sets which were investigated further using GSEA 
“leading edge” analysis. This analysis helps determine which genes are 
overrepresented (frequently present) within the group of 5 enriched 
extracellular matrix GO gene sets [92], and are therefore likely to be involved 
in these processes in the present study.  
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Figure 12. Leading edge analysis and qPCR reveal upregulation of Lumican in AGR3 
depleted VCaP cells.   
(A) Leading edge analysis of five AGR3-depletion enriched GO terms involved in extracellular 
matrix homeostasis (highlighted in Figure 11C). In the heatmap, white colour indicates 
absence from GO term. Red colour intensity indicates high rank (high fold change) within GO 
term, while blue colour intensity indicates low rank (low fold change). A white cell indicates an 
absent gene in signature. Arrows indicate genes selected for validation with qPCR.   
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(B) Gene expression and fold-change values (shAGR3 v.s. shCon) for the 5 overrepresented 
genes in the leading edges of significantly enriched extracellular matrix related GO gene sets. 
These fold-change and expression values were calculated by MAS 5.0 when comparing 
equivalent probe pair intensities in the HG U133 Plus 2.0 array chips for matching probe sets 
of shAGR3 and shCon samples.   
(C) AGR3, DMD, LUM, KAL1, COL5A2, and APLP1 mRNA expression was assessed by 
reverse transcribing total RNA from triplicate samples of three different shCon (C1-3) and 
shAGR3 (KD1-3) VCaP clones into cDNA followed by qPCR analysis with AGR3, DMD, LUM, 
KAL1, COL5A2, APLP1, and RibP0 specific primers. Relative gene expressions were 
averaged from three different experiments before estimating statistical significance. (* p<0.05, 
mean ± SD, ns = not significant, n = 3)  
 
 
 
Leading edge analysis determined a group of genes responsible for the 
enrichment of the 5 extracellular matrix related GO gene sets. Of these 
genes, only DMD (Dystrophin), LUM (Lumican), KAL1 (Kallmann syndrome 
1), COL5A2 (Collagen V, subunit A2), and APLP1 (Amyloid-like protein 1) 
were part of almost all 5 gene sets analyzed (e.g. CRSIP3 is not present in all 
gene sets, Figure 12A), and therefore the expression of these 5 genes was 
considered further. 
In the microarray experiment, all 5 of these genes are upregulated in 
VCaP cells with a stable AGR3 knockdown (Figure 12B). To confirm this 
result, expression of these 5 genes, and AGR3 as control, was investigated in 
control and AGR3-depleted VCaP cells by carrying out qPCR with cDNA 
reverse transcribed from total RNA in triplicate. This analysis confirmed stable 
AGR3 suppression, and revealed that Lumican, COL5A2, and KAL1, but not 
DMD or APLP1 were upregulated in shAGR3 VCaP cells (Figure 12C). In 
addition, Lumican upregulation determined with qPCR was found to be higher 
than that reported by the microarray experiment, and highest among the 
genes tested.  
Overall, this analysis reveals AGR3 involvement in a diverse set of 
functions that include extracellular matrix processes, and a link between 
AGR3 and Lumican gene expression. 
 
 
 
 
Results 
 76 
4.7. AGR3 affects VCaP cell migration in part by modulating Lumican 
expression 
 
Lumican is a secreted SLRP (small leucine-rich proteoglycan) 
implicated in cancer cell migration and adhesion [93-96]. In prostate cancer, 
external Lumican protein was shown to inhibit migration of LNCaP, PC-3, and 
DU145 cells [97].  
In the present study, AGR3 knockdown lead to Lumican mRNA 
upregulation, and a decrease in cell migration and adhesion. Together, these 
data suggest the possibility that AGR3 influences VCaP cell migration and 
adhesion by modulating Lumican expression. To test this hypothesis, the 
effect of Lumican on VCaP cell migration and adhesion was investigated in 
control and AGR3-depleted VCaP cells by transiently suppressing Lumican 
expression with siRNA.  
The expression of AGR3 and Lumican was determined in control and 
AGR3-depleted cells transfected for 72 h with either siLUM (anti-Lumican 
siRNA) or siGFP as control before assaying cell migration and adhesion. Total 
RNA and matching whole-cell lysate samples confirmed knockdown of the 
AGR3 and Lumican genes at both mRNA and protein level (Figure 13A and 
B). In addition, these experiments confirmed the previously observed (Figure 
12C) upregulation in Lumican expression in AGR3-depleted cells (Figure 13A, 
right chart, lane 3 and lane 1) at both mRNA (Figure 13A) and protein level 
(Figure 13B).  
To determine the effect of Lumican on VCaP cell migration, after 72 h 
of siRNA transfection, cells were stained with Vybrant DiI and platted in the 
upper chamber of BD cell culture insert wells. Normal growth medium 
containing 10% v/v FBS was used as chemo attractant in the lower chambers. 
Consistent with the previous results (Figure 10B), AGR3-knockdown VCaP 
cells showed reduced migration compared to control cells (Figure 13C, 
compare lane 3 with lane 1). Upon treatment with siLUM, migration of AGR3-
knockdown cells was significantly enhanced compared to the same cells 
treated with siGFP (Figure 13C, compare lane 4 with lane 3). Migration of 
these cells was no longer significantly different from siGFP-treated control 
cells (Figure 13C, compare lane 4 with lane 1), suggesting that suppression of 
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Lumican in AGR3-knockdown cells reverses the loss of migration due to 
AGR3 suppression. Together, these results suggest that AGR3 suppression 
affects VCaP cell migration in part by inducing upregulation of Lumican.   
 
Figure 13. AGR3 affects VCaP cell migration in part by modulating lumican expression.  
(A) After 72 h of transfection with either siLUM or siGFP as control, total RNA collected from 
control (shCon) and AGR3 knockdown (shAGR3) cells was reverse transcribed to cDNA, 
which was used as template in qPCR reactions with AGR3, LUM, and ribosomal protein 
RibP0 specific primers. Relative gene expression was computed for each gene against RibP0 
values. These charts represents the average of 3 independent experiments. (* p<0.05, mean 
± SD, ns = not significant, n = 3)  
(B) Transient knockdown of Lumican protein in control and AGR3-knockdown VCaP cells. 
Control (shCon) and AGR3-knockdown (shAGR3) VCaP cells were transfected with 120 pmol 
of either anti-Lumican siRNA (siLUM) or anti-GFP (siGFP) as control.  After 72 h, whole-cell 
lysates obtained from the transfected cells immunoblotted with Lumican, AGR3, and ß-actin 
antibody as control.   
(C) Migration of control and AGR3-knockdown cells pre-treated for 72 h with siLUM or siGFP 
was carried by staining cells with DiI dye and allowing them to migrate for 36h toward 10% v/v 
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FBS as described previously (Figure 10A). Significant differences were estimated using a 
one-tailed t-test. (* p<0.05, mean ± SD, ns = not significant, n = 3)  
(D) Substrate specific adhesion of control and AGR3-knockdown cells pre-treated for 72 h 
with siLUM or siGFP as control was carried out in fibronectin or Collagen I coated over 1 h as 
described previously (Figure 10B). A one-tailed t-test was used to evaluate significant 
differences between different treatments. (* p<0.05, mean ± SEM, n = not significant, n = 3) 
 
Given the previously described role of Lumican in cell adhesion, the 
possibility that reduced cell adhesion after AGR3 suppression (Figure 10C) 
depends on Lumican upregulation was considered next. Cell-substrate affinity 
was measured by seeding control and AGR3-knockdown cells pre-treated 
with either siLUM or siGFP for 72 h in fibronectin or collagen I coated culture 
dishes. Consistent with previous results (Figure 10C), AGR3 suppression 
resulted in reduced adhesion in AGR3-knockdown (shAGR3) cells compared 
to control cells (Figure 13D, compare lane 3 and lane 1 in fibronectin, 
significance of 0.074, and collagen I charts). However, no significant 
difference in adhesion was observed when comparing either siLUM to siGFP 
treated cells (Figure 13D, lane 4 and lane 3 in fibronectin and collagen I 
charts), suggesting that suppressing Lumican expression does not 
significantly reverse the reduction of cell adhesion to the substrates.  
Taken together, these results suggest that after AGR3 suppression, 
reduced migration, but not adhesion, depends in part on the upregulation of 
Lumican expression.  
                 To determine if the link between Lumican and AGR3 is limited to 
VCaP cells, Lumican gene expression was investigated at the mRNA level in 
control and AGR3 expressing 22Rv.1 cells. Triplicate cDNA reverse 
transcribed from total RNA sample was used as a template in qPCR reactions 
together with AGR3, Lumican, and RibP0 (ribosomal protein) specific primers 
as control. Consistent with AGR3 behavior in VCaP cells, Lumican mRNA 
expression was reduced in 22Rv.1 cells expressing AGR3 (Figure 14A).  
To determine if AGR3 expression in 22Rv.1 cells leads to effects 
consistent with those established in VCaP cells, the migration and adhesion of 
control and AGR3-expressing 22Rv.1 cells was determined next. Migration, 
assayed as described previously in Figure 10A, was increased in 22Rv.1 cells 
expressing AGR3 (Figure 14B). Adhesion assays, carried out as described in 
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Figure 10B, showed increased adhesion of AGR3-expressing 22Rv.1 cells to 
fibronectin, but not collagen I (Figure 14C) 
Overall, these results suggest that AGR3 can influence both adhesion 
and migration of prostate cancer cells, the latter of which depends at least in 
part on AGR3-mediated changes in Lumican expression.   
 
        
 
Figure 14. Overexpression of AGR3 in 22Rv.1 cells is associated with reduced Lumican 
mRNA expression and enhanced migration and adhesion. 
(A) AGR3 and LUM mRNA expression in either control or AGR3 overexpressing 22Rv.1 cells. 
Triplicate total RNA samples from control or AGR3 expressing 22Rv.1 cells were reverse 
transcribed into cDNA and used as template in qPCR reactions with AGR3, LUM, or RibP0 
specific primers. Relative AGR3 and LUM expression against RibP0 (* p<0.05, mean + SD, 
ns = not significant, n = 3)  
(B) Migration of control or AGR3 expressing 22Rv.1 cells was carried out over 36 h as 
described previously (Figure 10A), in 24-well BD cell culture inserts (Boyden chambers) over 
36 h using 10% v/v FBS as chemo attractant. The amount of fluorescent migrant cells was 
quantified using a spectrophotometer (excitation/emission 550/495 nm). (n = 2)  
(C) Substrate specific adhesion of control and AGR3 expressing 22Rv.1 cells was carried out 
as described previously (Figure 10B) in fibronectin and Collagen I coated 96-well plates, over 
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1 h under normal growth conditions. Substrate-specific adhesion is reported as % specificity, 
which is the signal of cells in coated wells expressed as a percentage of the signal from the 
same sample seeded in uncoated wells. (n = 2) 
 
 
4.8 AGR3 is upregulated during ER stress 
 
In addition to enhanced proliferation and migration, tumor cells are 
characterized by their increased capacity to survive physiological stress (i.e. 
hypoxia and nutrient starvation). Under these conditions, survival depends in 
part on enhanced ER (endoplasmic reticulum) activity, which ensures the 
correct processing of up to one-third of all proteins [98].  
The key constituents of the ER are molecular chaperones, which can 
simultaneously act as crucial regulators of survival signaling and direct 
effectors of protein folding. Molecular chaperones aid protein folding in the ER 
through a variety of mechanisms that include folding quality control and 
correct disulfide bond formation. The latter function is carried out by members 
of the PDI (protein disulfide isomerase) superfamily, which are molecular 
chaperones able to interact with the cystine moieties of other proteins through 
their thioredoxin-like protein folds. AGR3 is one of the smallest members of 
the PDI superfamily, with only one thioredoxin-like fold confirmed recently by 
the solution of its crystal structure [60]. The possible involvement of AGR3 in 
the cellular response to physiological stress has not been investigated. 
A typical consequence of physiological stress is accumulation of 
misfolded proteins in the ER lumen (a condition known as ER stress), to 
which cells react by upregulating the expression of several classes of 
molecular chaperones, including members of the PDI superfamily [56, 99]. To 
determine whether AGR3 expression is also upregulated during ER stress, 
AGR3 expression was monitored in VCaP cells exposed to three different ER 
stress inducing reagents.   
ER stress was induced by treating VCaP cells with Tg (thapsigargin, 
0.5 µM), Tm (tunicamycin, 0.5 µg/ml), DTT (dithiothreitol, 1 mM), or 1 µM 
H2O2 and their respective solvents (EtOH, DMSO (dimethylsulfoxide), and 
dH2O respectively) as control. Each of these reagents targets a crucial step in 
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ER protein maturation, such as disruption of ER Ca2+ homeostasis (Tg), N-
linked glycosylation (Tm), and perturbation of reductive (DTT) and oxidative 
(H2O2) reactions, and they all result in accumulation of misfolded proteins in 
the ER leading to ER stress. To determine the extent of ER stress induced by 
each treatment, the expression of GRP78 (glucose regulated protein 78 kDa, 
an ER-resident chaperone sensitive to ER stress) was also monitored at the 
protein level. Whole-cell lysates obtained after 12 and 24 h treatment with Tg, 
Tm, or DTT, and after 24 h with EtOH, DMSO, dH2O, and H2O2 were 
immunoblotted with AGR3, GRP78 and ß-actin antibodies as control. The 
protein level of AGR3 was increased in all treatments (Tg, Tm, DTT, and 
H2O2) to an extent consistent with the amount of ER stress induced, as 
indicated by the upregulation of GRP78 (Figures 15A and B).   
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Figure 15. AGR3 is upregulated during ER stress.   
(A) Expression of AGR3 after treatment with three different ER stress-inducing reagents. 
Whole-cell lysates of VCaP cells treated for 12 and 24 h with 0.5 µM thapsigargin (Tg), 0.5 
µg/ml tunicamycin (Tm), 1mM DTT, or H2O2, and for 24 h with EtOH, DMSO, or dH2O as 
control respectively, were immunoblotted with AGR3, GRP78, and ß-actin antibody as control.  
(B) Expression of AGR3 protein after treatment with 1 µM of H2O2 for 24 h. Whole-cell lysates 
obtained after 24 h of H2O2 or dH2O treatment as control were immunoblotted with AGR3, 
GRP78, and ß-actin antibody as control.   
(C) Comparison of the expression pattern of AGR3 and PDI during 36 h of ER stress. VCaP 
cells were treated for 36 h with 0.5 µM Tg or EtOH as control, and whole-cell lysates collected 
every 4 h for 24 h and at 36 after Tg treatment, as well as after 36 h of EtOH treatment. 
Whole-cell lysates were immunoblotted with AGR3, PDI, and ß-Actin as control.  
 
To further characterize the pattern of AGR3 expression during ER 
stress, a time course experiment was carried out in which whole-cell lysate 
samples were collected every 4 h for 24 h and at 36 h after treatment with 0.5 
µM Tg, or after a 36 h treatment with EtOH as control. Tg treatment was 
chosen because it gave the most pronounced effect of AGR3 upregulation. To 
further characterize expression during ER stress, AGR3 upregulation was 
compared to the upregulation of PDI, which is both the founding member of 
the PDI superfamily and another marker of ER stress [100]. Whole cell lysates 
collected at the indicated points were immunoblotted with AGR3, PDI, and ß-
actin antibody as control. Expression of both AGR3 and PDI protein reached 
maximum expression at 12 h after treatment. However, while PDI expression 
remained high even at 36 h of Tg exposure, the expression of AGR3 protein 
began to attenuate after 24 h and returned to basal levels by 36 h of 
treatment, suggesting an alternate mechanism of regulation during ER stress 
(Figure 15B). 
Together, these results demonstrate that, similar to other molecular 
chaperones, AGR3 is upregulated during ER stress.  
 
 
4.9. AGR3 is present in the endoplasmic reticulum of prostate cancer 
cells 
 
Molecular chaperones meant to deal with the accumulation of 
misfolded proteins during ER stress are typically found in the ER lumen (e.g. 
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GRP78 and PDI).  AGR3 contains an N-terminal ER-targeting signal, and an 
atypical C-terminal ER-retention tetrapeptide motif (QSEL). Despite the 
unusual sequence, the C-terminal motif of AGR3 was shown to be active in 
mediating ER localization in Hela cells (cervical cancer) [101]. Moreover, 
endogenous AGR3 has been detected in the ER of MCF7 breast cancer cells 
[57]. Together, these findings indicate that at least a portion of AGR3 protein 
localizes to the ER.  
To determine if AGR3 could play a role during ER stress in prostate 
cancer cells, the present study sought to first confirm its localization in the ER 
of prostate cancer cells using immunofluorescence. To reach maximal AGR3 
expression, VCaP cells were treated with 0.5 µM Tg for 12 h or EtOH as 
control. Cells were then fixed and permibilized prior to detecting AGR3 and 
GPR78 protein with specific antibodies, or staining nuclei with Draq5 (a DNA 
intercalator). In both EtOH and Tg (Figure 16A) treated VCaP cells, the AGR3 
signal (Figure 16A, I and V, red colour) was predominantly detected around 
the nuclei. A similar localization pattern was detected for GRP78 (Figure 16A, 
II and VI, green colour). Merging of these signals revealed yellow coloured 
regions (Figure 16A, IV and VIII), which indicate at least a partial overlap 
between AGR3 and GRP78 protein, and suggest the presence of an ER-
resident AGR3 protein fraction.   
To confirm this result in an additional prostate cancer cell line, control 
or AGR3-expressing (stable) 22Rv.1 cells were also treated with either 0.5 µM 
Tg or EtOH as control for 12 h before incubation with AGR3 and GPR78 
specific antibodies, as well as Draq5. A pattern of nuclear-adjacent signal 
similar to that observed for endogenous AGR3 in VCaP cells was detected for 
AGR3 and GRP78 in both EtOH and Tg treated 22Rv.1 cells (Figure 16B, IX 
and XIII, red colour / X and XIV, green colour respectively). Merging of these 
signals revealed a large degree of overlap between AGR3 and GRP78 
proteins (Figure 16B, XII and XVI, yellow colour), which provides further 
evidence of AGR3 localization in the ER.  
These results confirm the presence ER localization of endogenous 
AGR3 protein in VCaP cells, and indicate the establishment of such a fraction 
of overexpressed AGR3 in the ER of 22Rv.1 cells.  
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Figure 16. AGR3 is located in the endoplasmic reticulum of prostate cancer cells.   
Immunofluorescence analysis of the subcellular localization of AGR3 in VCaP and AGR3-
transfected 22Rv.1 cells.   
(A) Confocal images (40x magnification) of VCaP cells treated with EtOH (upper panel) or 0.5 
µM Tg (lower panel) for 12 h, and fixed with 4% v/v paraformaldehyde. AGR3 protein is 
shown in red (I and V), GRP78 protein, used here as a marker for the endoplasmic reticulum 
is shown in green (II and VI), while nuclei stained with Draq5 are shown in blue (III and VII). 
Merging of these three channels (IV and VIII) results in yellow colour (IV and VIII), which 
indicates overlap between AGR3 and GRP78 protein. The bar indicates 5 µm of length.  
(B) Confocal images of control (I – VIII), and AGR3-expresing (IX – XVI) 22Rv.1 cells treated 
with either EtOH (upper panels, I – IV, and IX – XIII) or 0.5 µM Tg (lower panels, V – VIII, and 
XIII – XVI) for 12 h, and fixed with 4% v/v paraformaldehyde. AGR3 protein is shown in red (I, 
V, IX, and XIII), GRP78 protein is shown in green (II, VI, X, XIV), while nuclei stained with 
Draq5 are shown in blue (III, VII, XI, XV). Merging of these three channels results in yellow 
colour (IV, VIII, XII, XVI), which indicates overlap between AGR3 and GRP78 protein.  
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All images were acquired with a Zeiss LSM510 confocal microscope using the LSM LSell5 
Image examiner software (Lecia Microsystems). The bar indicates 5 µm of length. 
 
 
 
4.10 AGR3 enhances the expression of GRP78 during ER stress. 
 
 
 
Upregulation of molecular chaperones is a key requirement of 
enhanced protein folding capacity during ER stress. In addition, cells activate 
a set of signaling pathways known as the UPR (unfolded protein response), 
which can execute either survival or apoptotic signaling, depending on the 
severity and persistence of ER stress. 
In the ER, UPR signaling and protein folding integrate in the activity of 
GRP78. In the absence of ER stress, GRP78 binds to and inactivates ER 
membrane-resident stress sensors which lie directly upstream of the UPR 
[102]. During ER stress, unfolded and misfolded polypeptides competitively 
titrate the GRP78 chaperone away from complexes with ER membrane-
sensors, leading to activation of the UPR and its downstream targets. 
Therefore GRP78, itself an upregulated molecular chaperone during ER 
stress, is a key indicator of the efficiency of cellular response to the 
accumulation of unfolded proteins.  
 To determine the effect of AGR3 on prostate cancer cell stress 
response, the level of GRP78 expression was monitored during ER stress in 
control and AGR3-knockdown VCaP cells treated with 0.5 µM Tg for 12 and 
36 h or for 36 h with EtOH as control. Total RNA collected at these time points 
was reverse transcribed into cDNA, which was used to monitor GRP78 
expression. Suppression of AGR3 levels did not alter the basal level of 
GRP78 mRNA. However, upon ER stress, GRP78 induction was lower in 
AGR3-knockdown (shAGR3) cells than control (shCon) cells, reaching 
significance at 36 h, and suggesting that absence of AGR3 leads to 
attenuated GRP78 upregulation during ER stress (Figure 17A).  
 To confirm this effect at the protein level, VCaP cells were similarly 
treated for 12, 24, and 36 h with 0.5 µM Tg or for 36 h with EtOH as control. 
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Whole-cell lysates obtained at these time points were immunoblotted with 
AGR3, GRP78, and ß-actin antibody as control. Consistent with results at the 
mRNA level, the basal GRP78 protein expression was not altered by 
suppression of AGR3. However, upon ER stress, GRP78 protein levels were 
lower in shAGR3 than shCon cells, especially at 24 and 36 h after treatment  
(Figure 17B).  
 To determine whether this effect was limited to VCaP cells, ER stress 
was similarly induced over 12 and 36 h with 0.5 µM Tg in AGR3-
overexpressing 22Rv.1 cells, and GRP78 was monitored at the mRNA and 
protein level.  
 
 
Figure 17. AGR3 enhances the expression of GRP78 at both protein and mRNA level in 
VCaP and 22R.v1 cells.    
(A) Effect of AGR3 suppression on the expression of GRP78 mRNA during ER stress in 
VCaP cells. Control (shCon) and AGR3-knockdown (shAGR3) VCaP cells were treated with 
0.5 µM Tg for 12 and 36 h or with EtOH (E) for 36 h as control. cDNA reverse transcribed 
from total RNA of each of these samples was used as template in qPCR reactions with 
GRP78 and RiBP0 primers as control. GRP78 expression was computed relative to RibP0 
expression. (* p<0.05, mean ± SD, ns = not significant, n = 3)    
(B) Effect of AGR3 suppression on the expression of GRP78 protein during ER stress in 
VCaP cells. Control and AGR3-knockdown VCaP cells were treated with 0.5 µM Tg for 12, 24 
VCaP
0
10
20
30
EtOH 12 36
Tg 0.5µM, time (h)
re
la
tiv
e 
G
R
P
78
 m
R
N
A
 e
xp
re
ss
io
n
clone shCon shAGR3
22Rv.1
0
2
4
6
8
EtOH 12 36
Tg 0.5µM, time (h)
re
la
tiv
e 
G
R
P
78
 m
R
N
A
 e
xp
re
ss
io
n
clone control AGR3
*
*
ns
ns
ns
A.
B.
C.
D.
  E  12   24  36  E  12   24  36   
15kDa— 
GRP78 
β-Actin 
70kDa— 
45kDa— 
AGR3 
shCon shAGR3 
Tg 0.5 µM, 
time (h) 
70kDa— 
45kDa— 
15kDa— 
β-Actin 
AGR3 
GRP78 
 E   12  36   E  12   36   
control AGR3 
Tg 0.5 µM, 
time (h) 
ns
 
Results 
 87 
and 36 h or with EtOH for 36 h as control. Whole-cell lysates collected at these time points 
were immunoblotted with AGR3, GRP78, and ß-actin antibody as control.  
(C) Effect of AGR3 overexpression on GRP78 mRNA levels during ER stress in 22Rv.1 cells. 
control and AGR3-expressing 22Rv.1 clones were treated with 0.5 µM Tg for 12 and 36 h or 
with EtOH (E) for 36 h as control. Relative GRP78 expression was computed by normalizing 
expression to RibP0 values. (* p<0.05, mean + SD, ns = not significant, n = 3)  
(D) Effect of AGR3 overexpression on GRP78 protein levels during ER stress in 22Rv.1 cells. 
control and AGR3-expressing 22Rv.1 clones were treated with 0.5 µM Tg for 12 and 36 h or 
with EtOH (E) for 36 h as control. Whole-cell lysates collected at these time points were 
immunoblotted with AGR3, GRP78, and ß-actin antibody as control.  
 
 
Basal GRP78 expression did not differ between control and AGR3-
expressing 22Rv.1 cells (Figure 17C). Upon ER stress, maximal GRP78 
mRNA induction was observed at 12 h after treatment with 0.5 µM Tg, 
however at this time point, GRP78 mRNA induction did not differ between 
AGR3-overexpression and control cells. After 36 h of Tg exposure, GRP78 
mRNA expression was significantly higher in AGR3-expressing than control 
22Rv.1 cells (Figure 17C). At the protein level, basal expression of GRP78 
was also not altered by AGR3 overexpression. However, by 36 h of treatment, 
GRP78 protein level was higher in AGR3-expressing than control 22Rv.1 
cells, suggesting enhanced cellular response to ER stress (Figure 17D).  
Taken together, these results indicate that AGR3 expression enhances 
prostate cancer cell response to ER stress.  
 
	  
 
 
4.11 AGR3 enhances prostate cancer cell viability during ER stress 
 
 
The positive influence of AGR3 on GRP78 expression during ER stress 
suggests enhanced cellular viability, which is defined as the ability of cells to 
retain and recover cellular function under normal or stress conditions.  
Viable cells are able to carry out the metabolic reactions necessary to 
produce energy and maintain synthesis of cellular components. Therefore, in 
in the present study, cell viability under ER stress was estimated by 
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monitoring the number of metabolically active cells using the Celltiter-Blue 
reagent.  
To determine the impact of AGR3 on cell viability, control (shCon) and 
AGR3-knockdown (shAGR3) VCaP cells, as well as control and AGR3-
expressing 22Rv.1 cells were exposed to 0.5 µM Tg or EtOH for 12 and 36 h. 
At each of these time points, the viability of Tg treated cells was assayed and 
reported as a percentage of the viability of EtOH treated cells.  
After 12 h of Tg treatment, the viability of AGR3-knockdown cells was 
significantly reduced when compared to the viability of control VCaP cells 
(Figure 18A). However, at 36 h, the viability of these cells did not differ. In 
22Rv.1 cells, after 12 h of Tg treatment, the difference in viability of control 
and AGR3-expressing clones did not reach statistical significance (Figure 
18B). After 36 h of treatment, a small, but statistically significant difference in 
the viability of AGR3-expressing cells was detected. 
Together, these experiments suggest that the presence of AGR3 
exerts a positive influence on the viability of prostate cancer cells during 
physiological stress.  
 
 
 
 
 
 
Figure 18. AGR3 enhances the viability of prostate cancer cells during ER stress.   
(A) Effect of AGR3 suppression on the viability of control (shCon) and AGR3-knockdown 
(shAGR3) VCaP cells. shCon and shAGR3 cells were seeded in 96-well cell culture plates, 
and treated with either EtOH or 0.5 µM Tg for 12 and 36 h. At each of these time points, 20 µl 
of Celltiter-Blue reagent was added to the cells and metabolized over 1 h before measuring 
fluorescence at 590 nm. % Viability was calculated by expressing fluorescence values of Tg 
treated as a percentage of corresponding EtOH treated cells at each time point. (* p<0.05, 
mean ± SD, ns = not significant, n = 3)    
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(B) Effect of AGR3 suppression on the viability of control and AGR3 overexpressing 22Rv.1 
cells. Control and AGR3-expressing 22Rv.1 cells were seeded in quadruplicate in 96 well cell 
culture plates, and treated using the same conditions described in (A). (* p<0.05, mean ± SD, 
ns = not significant, n = 3)   
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5. DISCUSSION 
 
 
Tumor markers reduce mortality by enhancing diagnosis and prognosis 
of cancer. Prostate cancer benefits from a number of diagnostic (e.g. PSA, 
prostate specific antigen) and prognostic markers (e.g. the TMPRSS2-ERG 
gene fusion, Transmembrane protease, serine 2 – v-Ets erythroblastosis virus 
E26 oncogene related). The discovery and characterization of additional 
markers holds promise in reducing the mortality associated with this disease. 
 AGR3 is a member of the PDI (protein disulfide isomerase) family that 
contains an atypical thioredoxin catalytic motif and N and C-terminal ER 
(endoplasmic reticulum) localization signals. Within the PDI family, AGR3 has 
a closely related homolog (~64% protein sequence homology) called AGR2, 
and both genes show increased expression in prostate cancer [31, 37, 85]. 
AGR2 is involved in multiple facets of prostate cancer progression [32, 34, 
103]. To date, the function AGR3 in prostate cancer has not been 
investigated.         
 The present study sought to characterize the expression and function 
of AGR3 in prostate cancer. Analysis of AGR3 expression in patients 
confirmed its upregulation in prostate cancer and revealed a possible 
association with aggressive disease. In prostate cancer cell lines, knockdown 
of endogenous AGR3 resulted in reduced proliferation while overexpression 
studies in three different prostate cancer cell lines showed that AGR3 could 
enhance cell proliferation. Proliferation could also be enhanced by 
extracellular AGR3, suggesting the possibility of autocrine action. AGR3 
knockdown reduced adhesion and migration, with the latter mediated in part 
by upregulation of Lumican, a small leucine-rich proteoglycan. Furthermore, 
the AGR3 expression is induced during ER stress, where it associated with 
enhanced cell viability. Together, these results support a role for AGR3 as 
a possible marker of prostate cancer progression. 
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5.1 AGR3 is associated with advanced prostate cancer 
 
  
The expression of AGR3 in prostate cancer has been previously 
reported [85]. The present study confirmed the upregulation of AGR3 mRNA 
in prostate cancer patients, and found an association between AGR3 
expression and the Gleason scores 8-10 (Figure 3A) in Oncomine datasets. In 
addition, the pattern of AGR3 expression differed from that of its close 
homolog AGR2, which is reported to be overexpressed in primary prostate 
tumors [76]. In the Oncomine datasets analyzed here, the expression of 
AGR2 was significantly upregulated only in the Gleason 1-7 category, 
consistent with its reported upregulation in primary tumors. These findings 
suggest an inverse correlation between AGR2 and AGR3 expression in 
prostate cancer progression. This notion is supported by a study carried out in 
our lab, which found mutual regulation of these genes: knockdown of AGR3 
lead to upregulation of AGR2, while knockdown of AGR2 resulted in 
increased AGR3 expression in VCaP cells [104]. Together, these results 
suggest that the inverse correlation of AGR2 and AGR3 expression in 
prostate cancer progression may depend in part on their mutual regulation.  
How this interaction is mediated remains unclear, although clues are 
offered by reports characterizing AGR2 and AGR3 expression in prostate 
cancer. For example, both AGR2 and AGR3 are AR (androgen receptor) 
regulated genes, and in prostate cancer, AR-dependent gene expression is 
controlled by the activity of FOXA1 (forkhead box A1) [68]. FOXA1 has been 
shown to control the promoter activity of AGR2 [40], and evidence suggests 
that AGR2 may in turn affect FOXA1 expression [104]. In addition, chip-seq 
data in LNCaP and VCaP cells reveal FOXA1 binding of the AGR3 promoter 
at several sites [30]. It is therefore conceivable that FOXA1 plays a role in the 
regulation of AGR3, and that AGR2 may indirectly affect AGR3 levels by 
altering FOXA1 expression.  
Nevertheless, AGR2 and AGR3 are also found co-expressed in some 
tissue types (e.g. ovarian cancer [57]). Therefore, the conditions that favor co-
expression, or a mutually exclusive pattern of expression may relate to the 
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cancer type, and could depend on any of the tumor-related functions of these 
genes.  
 
5.2 AGR3 enhances prostate cancer cell proliferation 
 
 
Increased expression in prostate cancer suggests a possible role for 
AGR3 in prostate cancer cell proliferation. In line with this view, suppression 
of endogenous AGR3 protein in pooled VCaP clones resulted in reduced cell 
proliferation, while AGR3 expression enhanced proliferation in the AGR3-
negative 22Rv.1, LNCaP and PC-3 cells, but did so at only moderate levels of 
expression. Higher amounts of AGR3 protein expression abrogated this effect 
(LNCaP and PC-3) and even inhibited proliferation (22Rv.1), indicating the 
possibility that forcing an artificially high level of expression has a detrimental 
effect on cell proliferation.  
Therefore, to eliminate the caveats associated with stable protein 
overexpression, the effect of AGR3 on cell proliferation was studied using an 
inducible-expression system in 22Rv.1 cells, the advantages of which include 
greater control of expression levels and genetic background (i.e. comparing 
induced to uninduced states of the same clone), as well as the absence of cell 
adaptation to stable gene expression overtime. Consistent with previous 
results, modulating AGR3 levels in the same cells (same clone) confirmed 
both enhanced proliferation (at moderate expression level) and reduced 
proliferation at high levels of AGR3 expression. Separately, inducing maximal 
expression in three different clones with varying maximal expression levels 
resulted in enhanced proliferation of the clone with the lowest expression 
level, and reduced proliferation in clones achieving a high level of AGR3 
expression.  
Taken together, these knockdown and overexpression studies suggest 
a positive role for AGR3 in prostate cancer cell proliferation. Since AGR3 
expression is highest in advanced stages of the disease, these findings 
indicate that AGR3 may promote an aggressive phenotype by enhancing cell 
proliferation.  
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5.3 AGR3 is a secreted protein able to promote prostate cancer cell 
proliferation 
 
Molecular chaperones are known to be secreted extracellular space 
where they play a diverse set of functions. One of the better-characterized 
functions of a secreted AGR protein is carried out by nAG, the newt homolog 
of human AGR2, the activity of which is crucial for limb regeneration. 
Extracellular nAG can strongly induce the proliferation of blastema cells in 
culture [46]. 
In the present study, secretion of AGR3 protein was confirmed in the 
medium of 22Rv.1 cells transfected with AGR3 cDNA, as well as in the 
medium of AGR3-inducible 22Rv.1 cells after induction. Subsequently, AGR3 
conditioned media generated from inducible 22Rv.1 cells were used in 
proliferation assays. 22R.v1 (control, not AGR3-inducible) and DU145 cells 
showed enhanced proliferation in the presence of AGR3. DU145 cells showed 
a more pronounced effect in this experiment, which is likely explained by the 
individual differences between DU145 and 22Rv.1 cells.  
Secreted nAG mediates its effect through interaction with Prod 1, which 
is a member of the LY6 cell-surface antigen family of proteins. In breast 
cancer, AGR3 was shown to interact with the extracellular domain of C4.4 
(GPI-anchored metastasis-associated protein C4.4A homolog), which is also 
a member of the LY6 family [43]. If this interaction is proven functional, 
individual differences in C4.4 expression between cell lines could eventually 
account for the observed differences of extracellular AGR3 in different cell 
lines. Taken together these results suggest a role for extracellular AGR3 in 
prostate cancer development. 
 
 
5.4 AGR3 enhances adhesion and migration in prostate cancer cells 
 
In prostate cancer progression, disregulated cell proliferation is 
typically followed by changes in adhesive interactions with the extracellular 
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matrix that eventually develop into enhanced cell migration. Increased 
migration is an enabling step in the progression to advanced disease, and 
given the elevated expression of AGR3 in advanced prostate cancer patients, 
a role was hypothesized for this gene in cell migration and adhesion.  
VCaP cells with a stable AGR3 knockdown showed reduced migration 
(using the Boyden chamber assay) and adhesion to substrate (collagen I and 
fibronectin). To confirm this result, similar migration and adhesion 
experiments were carried out using 22Rv.1 cells with stable AGR3 
expression, which yielded enhanced migration and adhesion to substrate. 
Together these results, suggest a positive effect of AGR3 on prostate cancer 
cell migration and adhesion.  
 To understand how AGR3 accomplishes these effects, data from a 
genome-wide expression experiment of VCaP cells with a stable AGR3 
knockdown was analyzed for GO gene set enrichment. The expression 
changes induced by the knockdown of AGR3 were enriched with GO terms in 
development and extracellular matrix-related categories.  
Enrichment of development-related GO terms is consistent with the 
reported functions of AGR3 homologs in X. laevis development, and suggests 
human AGR3 involvement in prostate morphogenesis [38, 39]. At present, 
there are no knockout mice models of AGR3 available and the effect of this 
gene in prostate development remains unknown. Moreover, the effect of the 
highly related AGR2 in prostate development has not been studied in 
knockout mice either. A clue as to how development-related functions of 
AGR2 and AGR3 could contribute to prostate cancer progression is held in a 
single report, which determined a function of AGR2 in establishing a 
neuroendocrine phenotype in prostate cancer cells, a finding made likely by 
the involvement of AGR2 and AGR3 homologs in neural patterning of the X. 
Laevis forebrain [38, 103]. The role of AGR3 in prostate development and 
prostate cancer cell phenotype (i.e. luminal v.s. basal v.s. neuroendocrine) 
could be further investigated.  
The second category of GO enrichment includes five extracellular 
matrix-related terms related to cell migration and adhesion. Further analysis of 
these terms revealed a core group of genes driving enrichment, the 
expression of which was subsequently verified using qPCR. Significant 
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upregulation was confirmed for LUM (Lumican), KAL1 (Kallmann syndrome 1) 
and COL5A2 (Collagen V, subunit A2) gene expression, and of these, LUM 
exhibited high expression values in both microarray (high raw signal) and 
qPCR experiments suggesting its abundance in VCaP cells. A reciprocal 
reduction of LUM expression was observed in 22Rv.1 cells stably expressing 
AGR3. Given previous reports implicating LUM in cell migration and adhesion, 
the relationship between LUM and AGR3 was explored further in the context 
of VCaP cell migration and adhesion [93, 94, 96, 97].  
LUM is a member of the SLRP (small leucine-rich proteoglycan) family 
of proteins involved in regulating collagenous matrix assembly. LUM shows 
opposite roles in non-cancer and cancer cell systems. For example, in the 
corneal epithelium of mice, it stimulates cell migration in an Erk1/2-dependent 
manner [105]. In contrast, in melanoma and prostate cancer cells (e.g. PC-3, 
DU145, and LNCaP) it was shown to inhibit both migration and invasion [93, 
94, 97]. These reports imply a negative impact of LUM expression on cancer 
cell migration, and suggest that its upregulation in AGR3-depleted VCaP cells 
can help explain the reduced migration of these cells.  
 In the present study, upregulation of LUM in AGR3-depleted VCaP 
cells was confirmed at both mRNA and protein levels. In addition, transient 
suppression of LUM expression revealed that upregulation of LUM in VCaP 
cells with stable AGR3 suppression is in part responsible for the decreased 
migration, but not adhesion, observed. This result is consistent with the 
previously described function of LUM in prostate cancer cell migration [97].  
 How AGR3 suppression leads to LUM upregulation is currently unclear. 
The LUM gene promoter has been studied, and is reported to be under the 
influence of an Sp3 (specificity protein 3) enhancer and an upstream 
suppressor motif matching GATA (GATA binding protein) response elements 
[106]. However, out of the 6 known GATA transcription factors in H. sapiens, 
those mediating LUM suppression have not yet been identified. The 
transcriptome analysis carried out in the present study showed changes in 
expression of a large number of genes with GATA1 response elements in 
their promoter, indicating altered activity of this transcription factor in AGR3-
depleted VCaP cells. GATA1 could therefore be responsible for the increase 
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in LUM expression in these cells.  How AGR3 alters GATA1 activity is 
unclear.   
 
5.5 AGR3 protein expression is enhanced during ER stress, and is 
required for full cellular response to ER stress and preservation of cell 
viability  
 
In the tumor microenvironment, cells experience physiological stress 
under a variety of adverse conditions such as hypoxia, oxidative stress, lack 
of nutrients, or changes in physiological pH. Typically, exposure to these 
conditions generates a surplus of unfolded protein in the ER, which is 
accompanied by upregulation of ER-resident chaperones meant to alleviate 
the excess protein burden. AGR3 is part of the protein disulfide isomerase 
family, members of which act as chaperones of protein folding in the ER. The 
protein sequence of AGR3 codes for an ER localization signal, an ER 
retention signal, and a thioredoxin fold, suggesting a possible role for AGR3 in 
protein folding in the ER.  
Two of the most common properties of molecular chaperones that deal 
with protein folding in the ER, are upregulation during ER stress and ER 
localization. ER localization of AGR3 was confirmed using 
immunofluorescence to track AGR3 and GRP78 (ER resident chaperone, 
marker of the ER organelle) in VCaP and AGR3-expressing 22Rv.1 cells. 
Overlap between AGR3 and GRP78 signals indicated ER localization of 
AGR3 in prostate cancer cells, and confirmed its previously reported 
localization the ER compartment [101]. In addition, AGR3 protein upregulation 
was detected after treatment with four different ER stress-inducing reagents: 
Ca2+-depleting (thapsigargin), glycosylation-inhibiting (tunicamycin), reducing 
(dithiothreitol) and oxidizing (H2O2). Together, these experiments provide 
evidence for AGR3 involvement in processes that mitigate ER stress.  
AGR3 protein reached maximal expression at 12 h after stress, and 
attenuated after that, until endogenous levels were reached again at 36 h. 
This pattern of expression differed from that of PDI, which maintained high 
levels even after prolonged (36 h) of ER stress. Loss of AGR3 protein after 
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prolonged stress suggests a role for AGR3 in the early moments of ER stress, 
when cells typically attempt to mount a pro-survival response. During ER 
stress, cells attenuate protein translation to prevent additional burden to the 
ER therefore indicate be a function of the protein stability of AGR3. Future 
studies determining protein stability (i.e. cycloheximide time course) could be 
used to determine the stability of AGR3 protein, and gain insight into its 
regulation. 
The expression pattern of AGR3 was mirrored by cell viability during 
ER stress. VCaP cells with a stable AGR3 knockdown showed reduced 
viability at 12 h after the application of stress, but showed no difference from 
controls after 36 h. The opposite effect was observed in 22Rv.1 cells, where 
stable AGR3 expression provided no significantly enhanced viability in the 
early moments of ER stress (12 h), but did produce a statistically significant 
enhancement at 36 h after treatment. The absence of enhanced viability at 12 
h in 22Rv.1 cells could be explained by the fact that these cells have no 
endogenous AGR3 expression and could have adapted to maximizing viability 
during the early stage of ER stress in its absence.  
The influence of AGR3 during ER stress was additionally estimated by 
monitoring GRP78 expression, which is indicative of the cells response to ER 
stress. Inducing stress in VCaP cells with a stable AGR3 knockdown resulted 
in attenuated GRP78 expression at both mRNA (significant at 36 h) and 
protein levels, that when coupled to reduced cell viability suggests an 
attenuated response to ER stress. Conversely, in 22Rv.1 cells with a stable 
AGR3 expression, GRP78 levels were significantly increased at the both 
mRNA level and protein level after 36. Given that cell viability was also 
enhanced at this time point, this result suggests that the presence of AGR3 
exerts a positive influence on the cells response to ER stress. Combined, 
these results suggest that AGR3 protein expression is enhanced during ER 
stress, and that its presence is required for maximal cell viability.  
Given that AGR3 catalytic motif (CxxS), one possible reason for 
reduced viability in the absence of AGR3 may be the reduced folding 
capacity. The same catalytic motif is present in AGR2, and is implicated in the 
processing of mucin proteins in the ER. The possibility of AGR3 performing a 
similar function is reflected in its tissue expression pattern. AGR3, like AGR2, 
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is typically expressed in mucin-producing tissues (i.e. lungs, stomach, 
intestine, https://www.nextbio.com), as well as mucinous ovarian cancer [57].  
Future studies could mutate the active residues of this catalytic motif before 
testing viability in VCaP cells (dominant negative experiments) or 22Rv.1 cells 
(overexpression experiments), to ascertain whether the thioredoxin motif of 
AGR3 plays a role in cell viability. Reduced viability in these experiments 
could suggest that AGR3 functions in part by interacting with client molecules, 
possibly by forming mixed disulfide bonds.  
Taken together, these results suggest that AGR3 bears the classic 
features of a molecular chaperone (i.e. is upregulated during ER stress, and 
localizes in the ER), and possibly plays an important role in enhancing 
prostate cancer cell survival in the challenging conditions of the tumor 
microenvironment.  
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6. CONCLUSIONS  
 
AGR3 is upregulated in the later stages of prostate cancer where 
tumors are typically aggressive (i.e. progress rapidly through subsequent 
stages) and metastatic. Similar to AGR2, the expression of AGR3 enhances 
the migration and adhesion of tumor cells. This finding is important when 
considering the inverse correlation between AGR2 and AGR3 expression in 
prostate cancer patients. It is possible that in the advanced stages of prostate 
malignancy, the migratory phenotype of aggressive disease is maintained by 
upregulated AGR3 in the absence of AGR2. Moreover, AGR3 appears to 
enhance cell migration in part through suppression of Lumican, which is 
another extracellular matrix protein and tumor suppressor. How AGR3 affects 
Lumican expression could be further investigated.     
 Consistent with its expression at advanced stages of prostate cancer, 
AGR3 appears to exert a positive effect on tumor growth by enhancing 
hallmark features of aggressive disease such as cell proliferation and cell 
viability. Importantly, AGR3 appears able to carry out these functions 
independent of cell type. In addition, the presence of extracellular AGR3 was 
confirmed, and its involvement in cell proliferation was demonstrated. Given 
its effect on tumor growth, this aspect of AGR3 biology is particularly relevant 
for two reasons: 1. AGR3 may act in a paracrine fashion to enhance 
proliferation of adjacent cells that do not express it, 2. an assay could be 
developed to detect extracellular AGR3 for use as a diagnostic or prognostic 
marker in prostate cancer.         
 Taken together, the findings of this study establish the importance of 
AGR3 in prostate cancer biology, and rationalize further consideration of this 
protein as a potential marker of prostate cancer progression. 
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